

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/109898/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Schwarze, J., Openshaw, P., Jha, A., Del Giacco, S.R., Firinu, D., Tsilochristou, O., Roberts, G., Selby, A., Akdis, C., Agache, I., Custovic, A., Heffler, E., Pinna, G., Khaitov, M., Nikonova, A., Papadopoulos, N., Akhlaq, A., Nurmatov, Ulugbek ORCID: <https://orcid.org/0000-0002-9557-8635>, Renz, H., Sheikh, A. and Skevaki, C. 2018. Influenza burden, prevention, and treatment in asthma- A scoping review by the EAACI Influenza in asthma task force. *Allergy* 73 (6) , pp. 1151-1181. 10.1111/all.13333 file

Publishers page: <http://dx.doi.org/10.1111/all.13333>  
<<http://dx.doi.org/10.1111/all.13333>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



**Influenza burden, prevention and treatment in asthma – a scoping review**  
**by the EAACI Influenza in Asthma Task Force**

Jürgen Schwarze<sup>1</sup>, MD, PhD, Peter Openshaw<sup>2</sup>, FMedSci, Akhilesh Jha<sup>2</sup>, MRCP (UK), Stefano R del Giacco<sup>3</sup>, MD, Davide Firinu<sup>3</sup>, MD, Olympia Tsilochristou<sup>4</sup>, MD, Graham Roberts<sup>5</sup>, DM, FRCPC, Anna Selby<sup>5</sup>, BM BCh, Cezmi Akdis<sup>6</sup>, MD, PhD, Ioana Agache<sup>7</sup>, MD, PhD, Adnan Custovic<sup>8</sup>, MD, PhD, Enrico Heffler<sup>9</sup>, MD, PhD, Georgia Pinna<sup>10</sup>, MD, Musa Khaitov<sup>11</sup>, PhD, Alexandra Nikonova<sup>11</sup>, Nikolaos Papadopoulos<sup>12</sup>, MD, PhD, Ather Akhlaq<sup>13</sup>, PhD, Ulugbek Nurmatov<sup>14</sup>, Harald Renz<sup>15</sup>, MD, Aziz Sheikh<sup>16</sup>, FRSE, FMedSci, Chrysanthi Skevaki<sup>15</sup>, MD, PhD

**Author affiliations:**

<sup>1</sup> Centre for Inflammation Research, University of Edinburgh, The Queens Medical Research Institute, Edinburgh, UK

<sup>2</sup> Respiratory Sciences, National Heart and Lung Institute, Imperial College London, UK

<sup>3</sup> Department of Medical Sciences and Public Health “M. Aresu”, University of Cagliari, Cagliari, Italy

<sup>4</sup> Department of Pediatric Allergology, King’s College, London, UK

<sup>5</sup> Faculty of Medicine, University of Southampton, Southampton and David Hide Asthma and Allergy Centre, St Mary’s Hospital, Newport, Isle of Wight, UK

<sup>6</sup> Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland

<sup>7</sup> Department of Allergy and Clinical Immunology, Faculty of Medicine, Transylvania University Brasov, Brasov, Romania

<sup>8</sup> Department of Paediatrics, Imperial College London, UK

<sup>9</sup> Personalized Medicine, Asthma and Allergy Clinic, Department of Biomedical Sciences, Humanitas University, Milan, Italy

<sup>10</sup> Department of Medical Microbiology, National Kapodistrian University of Athens, Athens, Greece

<sup>11</sup> National Research Center Institute of Immunology of Federal Medicobiological Agency, Moscow, Russia

<sup>12</sup> Division of Infection, Inflammation & Respiratory Medicine, The University of Manchester, Manchester, UK and Allergy Dpt, 2<sup>nd</sup> Paediatric Clinic, National Kapodistrian University of Athens, Greece

<sup>13</sup> Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK

<sup>14</sup> Department of Health and Hospital Management, Institute of Business Management, Korangi Creek, Karachi - 75190, Pakistan

<sup>15</sup> Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, University Hospital Giessen & Marburg, Marburg, Germany

<sup>16</sup> Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK

**Author for correspondence**

Chrysanthi Skevaki, MD, PhD

Institute of Laboratory Medicine, Philipps University Marburg

Baldingerstrasse, 35043 Marburg, Germany

Phone +49 6421 586 6235

email: [Chrysanthi.Skevaki@uk-gm.de](mailto:Chrysanthi.Skevaki@uk-gm.de)

**Key words:** Viral infection, vaccination, antivirals, respiratory, health care utilization

**Short title:** Influenza burden in asthma – a scoping review

## **Abstract**

To address uncertainties in the prevention and management of influenza in people with asthma, we performed a scoping review of the published literature on influenza burden; current vaccine recommendations; vaccination coverage; immunogenicity, efficacy, effectiveness and safety of influenza vaccines; and the benefits of antiviral drugs in people with asthma. We found significant variation in the reported rates of influenza detection in individuals with acute asthma exacerbations making it unclear to what degree influenza causes exacerbations of underlying asthma. The strongest evidence of an association was seen in studies of children. Countries in the European Union currently recommend influenza vaccination of adults with asthma; however, coverage varied between regions. Coverage was lower among children with asthma. Limited data suggest that good seroprotection and seroconversion can be achieved in both children and adults with asthma and that vaccination confers a degree of protection against influenza illness and asthma related morbidity to children with asthma. There were insufficient data to determine efficacy in adults. Overall, influenza vaccines appeared to be safe for people with asthma. We identify knowledge gaps and make recommendations on future research needs in relation to influenza in patients with asthma.

## **Introduction**

Asthma is a heterogeneous chronic inflammatory lung disease characterized by intermittent airflow obstruction and increased reactivity to bronchoconstrictive triggers. Presently, an estimated 300 million people worldwide suffer from asthma (1). In Europe, more than 30 million people are affected, with six million suffering severe symptoms and 1.5 million life-threatening attacks (2). Asthma onset and acute asthma exacerbations (AAE) have been strongly associated with respiratory viral and (to a lesser extent) bacterial infections (3-11)

Influenza viruses cause respiratory infections, typically during winter months. Most significant disease is caused by influenza A and B, which may escape immune pressure by undergoing antigenic drift and recombination; such genetic changes lead to new subtypes, which can cause epidemic or pandemic outbreaks (12, 13). Each year, influenza virus infection affects 5 to 20% of the global population (14), while annual vaccination greatly contributes to reduce related morbidity and mortality (15). Upon vaccination, coordinated activity of innate and adaptive immune responses leads to generation of short- and long-lived antibody producing plasma cells and memory B cells. The importance of influenza as a cause of serious illness and AAE is increasingly appreciated (16, 17). Despite uncertainties about their effectiveness, influenza vaccines are widely recommended for those with asthma (18).

To address uncertainties over the prevention and management of influenza in patients with asthma, we performed a scoping review and discuss the current knowledge of the burden imposed by influenza on patients with asthma, current vaccine recommendations and vaccination coverage in various regions, the evidence regarding immunogenicity, efficacy, effectiveness and safety of influenza vaccines, and the possible benefits of antiviral drugs in patients with asthma. We conclude by identifying knowledge gaps and future research needs in relation to influenza in asthma patients.

## **1. Methods**

We systematically searched relevant published, unpublished and in-progress original research and systematic reviews that were pertinent to the subject matter of this EAACI

Task Force. This involved searching databases of peer-reviewed published literature (Cochrane Library, EMBASE and CINAHL, MEDLINE and Google Scholar) and research in progress (i.e. <http://www.controlled-trials.com/> and <http://www.clinicaltrials.gov/>) for the period 2000–2015. In addition, we wrote to a panel of international experts in an attempt to identify additional unpublished or in-progress work. There were no restrictions on language of publication.

We were particularly interested in randomized controlled trials (RCTs) on questions relating to the immunogenicity, efficacy and/or effectiveness of influenza vaccine among asthmatics, and epidemiological studies relating to the influenza incidence/prevalence and public health burden and safety of influenza vaccine. Systematic reviews with or without meta-analysis were of interest if they focused on any of the questions of interest.

The searches (see Appendix 1) were undertaken and allocated to relevant sub-group leads depending on the focus of the inquiry. Where possible, studies reported in languages other than English were translated. Within subgroups, two reviewers independently reviewed the titles and if necessary abstracts of potentially eligible studies to decide on eligibility; disagreements on study eligibility were resolved through discussion among the reviewers. Studies were then – in the specific context of asthma/allergy – categorized by topic area, namely: i) Global burden of influenza; ii) Influenza vaccination recommendations and coverage; iii) Immunogenicity of influenza vaccines; iv) Efficacy of influenza vaccines; v) Effectiveness of influenza vaccines; vi). Safety of influenza vaccines; and vii). Antiviral treatments against influenza. Reports were then scrutinized and interpreted by experts on the subject matter. Any disagreements on issues to do with interpretation were resolved through discussion.

The searches were first conducted in 2014 and then updated in October 2015. The key characteristics and findings of all eligible studies were summarized in data tables, and the findings narratively synthesized. These are presented by topic in Table 1.

## **2. Global burden of influenza in patients with asthma**

### **2a. Influenza-attributable health care utilization in asthma patients**

Asthma is the most common underlying disease in patients with influenza admitted to healthcare facilities, both in adults (19-33) (7.6–46% (34, 35)) and children (26, 36-47) (8.3–42% (48, 49)). Children with asthma accounted for a significantly larger proportion of those hospitalized with pandemic H1N1 than with seasonal influenza (24, 50-53). Asthma was also the most common comorbidity among pregnant women hospitalized with H1N1 infection, with a prevalence ranging from 8-33% (54-57).

Asthma represented a risk factor for hospitalization during influenza seasons in the general population (58), with an OR of 2.6 (95% CI 1.6–4.0) in two Canadian studies (59, 60), and a relative risk (RR) of 4.47 (95% CI 1.49–13.39) in Israel (61). The same applied to children (47, 62, 63), where asthma conferred a 4-fold risk of hospitalization (USA (64), Germany (41), and Argentina (65)), with a 21-fold risk observed in South Korea (66). Interestingly, influenza-related hospitalization costs in children with asthma may be lower than in children with other chronic conditions, and were very close to costs in children without comorbidity (67).

Asthma patients seemed to have a higher risk of being admitted to the intensive care unit (ICU) or to have a more severe disease course when hospitalized for influenza (26, 33, 43, 45, 50, 66, 68-70), with an OR of 4.92 (95% CI 1.38–17.33) in Argentinian children (69) and a RR of 15.20 (95% CI 1.16-199.63) in China >15 years of age (71). Severe disease was especially common in those developing pneumonia (33), but did not seem to be related to the severity of underlying asthma (51). In a multivariate

analysis of H1N1 pediatric patients, asthma was associated with increased mortality in ICU-admitted children and adolescents (OR 1.34,  $p=0.05$ ) (68). However, a retrospective analysis performed in the UK on 1,520 patients showed that patients with asthma hospitalized because of influenza A infection were less likely to require ICU or die compared with those without asthma, with an OR of 0.51 (95%CI 0.36–0.72) for severe outcome (28). Two other studies confirmed this finding (25, 29), which may be even more pronounced in those with pre-admission inhaled (OR 0.34; 95% CI 0.18–0.66) or systemic corticosteroid treatment (OR 0.36 95% CI 0.18–0.72) for asthma and an earlier hospital admission (within 4 days from symptom onset - adjusted OR 0.60 95%CI 0.38–0.94) (28).

## **2b. Influenza-induced acute asthma exacerbations**

Influenza, like other respiratory viral infections, can lead to AAE and was found to account for 32.0% (72) and 9.8% (73) of AAEs in two studies of adults with asthma outpatients. However, the method used to identify the presence of influenza in AAE episodes largely determines the outcome. A direct comparison of molecular (PCR), serological, and immunofluorescent (IFA) detection in the same cohort of adults with asthma found influenza rates of 24.0%, 18.3%, and 2.0% respectively in AAEs (74). Thus, the validity of studies that applied conventional influenza identification techniques such as cytopathic effect in cell culture followed by indirect immunofluorescence to confirm viral presence (75) is questionable. Among hospitalized adults with asthma patients, rates of influenza-induced AAE were reported at 10.0% (76), 19.0% (77), 20.7% (78), and as high as 37.9% (73).

Available data on influenza-associated AAE among children vary considerably. For outpatient visits, three studies did not detect any influenza-positive samples (75, 79, 80), while several groups identified influenza infection as the cause of AAE, with most reporting rates of influenza-positive samples between 2.4% and 15.5% (63, 81-84). A recent study showed an accentuated propensity for loss of asthma control when children were infected with pH1N1 (38%) compared with other common respiratory virus infections (85). Among children with asthma hospitalized for severe AAE, three studies reported an influenza-associated burden of 2.6% (82), 3.4% (86) and 3.7% (63) of AAEs. In summary, there were significant inter- and intra-group variations in the reported influenza-induced AAE burden among children and adults with asthma, with fewer studies on adults.

Various factors compromise the interpretation of the available data. First, the use of different diagnostic methods for influenza detection may significantly influence the study outcome. The advent of molecular techniques and their universal use may solve this issue. Second, the absence of harmonized criteria for appropriate inclusion of patients and the lack of a standardized definition and diagnosis of influenza infection disallow direct comparison of results and complicate the identification of relevant studies. Third, the lack of large cohorts of patients with asthma studied for influenza induced AAE, raises questions about the validity of the currently available findings. Furthermore, seasonal rather than perennial influenza testing and selective testing only in hospitalized AAE cases could lead to inaccurate estimation of the actual contribution of influenza to AAEs.

## **3. Current influenza vaccine recommendations and coverage for people with asthma**

In common with most economically-developed nations (Fig. 1), all 28 countries of the European Union currently recommend influenza vaccination of people with chronic respiratory disease, including asthma (87-89). Trivalent (TIV) and quadrivalent

inactivated split-virus influenza vaccines are available, with TIV the most widely used throughout the EU. An intradermal vaccine is also available and more recently a quadrivalent live attenuated intranasal vaccine (LAIV) was approved for use in the UK in children aged 2–18 years (88, 90).

However, vaccine uptake for clinical risk groups varied from 31% in Portugal to 82% in Northern Ireland (88, 91), as did influenza vaccination coverage of adults with asthma, with 30–50% in Spain (92-95) and 40% in the UK (96). Self-reported uptake of seasonal influenza vaccine amongst adults with asthma in the US varied from 54% in the community to 71% in secondary care (97). Children with asthma had significantly lower coverage rates of approximately 18-20% in Spain (93, 98), 15% in France (99) and 2.5–20% in Italy, across multiple seasons (91). In comparison, in the USA vaccination coverage reached around 50% in adults and children (100).

To address the question of such historically low vaccination rates amongst those with asthma, many studies employed cross-sectional surveys to analyse the socio-demographic variables that predict vaccine uptake. The strongest factors associated with higher vaccine coverage, were older age, recent contact with healthcare providers, non-smoking status, presence of co-morbidities, more severe asthma, and (surprisingly) lower household income (92-95, 100-106), although regarding there are conflicting reports for the latter (98). Variables that were associated with lower vaccination uptake included younger age groups (96, 100, 107, 108), belonging to certain ethnic groups (102, 105, 108) and lack of awareness about the vaccine (91, 99, 100). A more detailed exploration assessing health attitudes suggested that the misbelief that the vaccination was not necessary or could actually cause influenza or side effects was predictive of non-adherence (97, 109-112) and contributed to lower vaccination coverage (96, 107, 108). Reports of low effectiveness probably also contributed to poor uptake (18, 113, 114).

Healthcare worker endorsement of vaccination was highly predictive of adherence (109, 110, 112). A survey of 1225 US allergists suggested that 85% of these offered influenza vaccinations to adults and children. Younger allergists (<45 years) were more likely to offer vaccination, especially to children (115). Pediatricians were more likely than family physicians to routinely recommend influenza vaccination to children with asthma (adjusted OR 3.49, 95% CI 1.68-7.22), with decisions also being made depending on asthma phenotype (i.e. intermittent vs. persistent) (116).

The success of vaccination programmes was affected by complex factors such as the nature of healthcare provision (e.g. free care or insurance based), education levels, and cultural acceptance of the vaccine. Therefore, national health surveys with information on vaccination status linked with medical and socio-demographic details, (such as that of Spain with data spanning more than two decades (92-95, 117) can aid in assessing the impact of influenza vaccination, at population level.

Simple interventions such as allowing for year-round scheduling of appointments for vaccination can be effective (118). Nevertheless, it is likely that only major policy shifts will lead to significantly higher vaccination rates, due to more clear and consistent messaging about the importance and acceptability of influenza vaccination to patients and healthcare workers alike. This is illustrated by the increase in influenza vaccination uptake among children with asthma from 36% (2005–2006) to 50% (2010–2011) after the US Centre for Disease Control and prevention (CDC) advised vaccinating all children, regardless of risk (100). With its favourable safety and cost-benefit profile (18, 119, 120) there is a need for health campaigns to raise awareness amongst the public and clinicians of the benefits of influenza vaccination and to improve implementation of guidelines.



#### **4. Immunogenicity of influenza vaccines in asthma**

There is uncertainty about the level of protection that influenza vaccines afford in people with asthma. Influenza vaccine immunogenicity, a prerequisite for protection, is usually assessed by haemagglutinin inhibition assay (HI) measuring seroprotection rate (percentage of subjects with antibody titres  $\geq 1:40$ ), seroconversion rate (percentage of subjects with  $\geq 4$ -fold increase in antibody titre), antibody geometric mean titre (GMT), and GMT ratio (GMT post vaccination/GMT pre-vaccination).

We identified limited data on influenza vaccine immunogenicity in asthma. Only one study of TIV in children aged 0.5–3 years compared healthy controls to recurrent wheezers. It found good and similar seroconversion and seroprotection rates to all three vaccine strains (H1N1, H3N2, and B) in both groups (after 1 month), with higher pre- and post-vaccination GMTs in children with wheeze, but a higher GMT ratio in healthy controls (121). In children with asthma, TIV and a virosomal inactivated subunit influenza vaccine induced good seroprotection and seroconversion at 1 month in both pre-school and school-age children, with some reduction in GMTs by 6 months (122, 123). A 2009 H1N1 vaccine given to adolescents and adults induced equally good seroprotection if 15  $\mu\text{g}$  or 30  $\mu\text{g}$  vaccine were given in those with mild-to-moderate asthma. In contrast, in severe asthma the higher dose resulted in better seroprotection, which in elderly severe asthma patients ( $\geq 60$  years) was only achieved with the high 30  $\mu\text{g}$  dose (124). In the latter group and in young children with recurrent wheeze, corticosteroid treatment or corticosteroid dose did not influence influenza vaccine immunogenicity (121, 124).

#### **5. Efficacy of influenza vaccines in asthma**

Data on the efficacy of influenza vaccination in asthma are limited, with only two randomized studies addressing the efficacy of TIV in patients with stable asthma. One study, conducted in Turkey, included 128 adults with asthma who received either TIV or no vaccination (125). No significant difference in the frequency of upper respiratory tract infections (URTI) or AAE rate was found between vaccinated and non-vaccinated participants; however, this study had significant limitations (see Table 1). In a larger randomized, double-blind, placebo-controlled trial from the Netherlands (81) in 6–18 year-old children with asthma, TIV had no significant effect on the number, severity, or duration of AAEs caused by confirmed influenza infection, or on the respiratory symptoms recorded; however, it moderately improved quality of life during the weeks of influenza-positive illness (126). In contrast, a conference abstract (127) reported significantly lower AAE rates in children  $< 5$  years with asthma following TIV (13%) compared with placebo (53%).

For LAIV, we found no efficacy data in asthma compared to non-vaccination. A large European multi-center, randomized, open-label trial compared intranasal cold-adapted LAIV to intramuscular TIV in children and adolescents aged 6–17 years with asthma, and reported a 34.7% reduction in culture-confirmed influenza illness after LAIV (128). A re-analysis of efficacy data from two randomized, multinational trials (129, 130) comparing LAIV to TIV, demonstrated that 2–5 year old children with mild-to-moderate asthma or prior wheezing, receiving LAIV had fewer cases of culture-confirmed influenza illness than TIV recipients (131).

#### **6. Effectiveness of influenza vaccination in asthma**

While efficacy studies reflect a treatment's performance in tightly controlled clinical trials, effectiveness studies reflect how well a treatment works in practice and are more representative of real life. Influenza vaccination may be less effective than expected



due to differences between the characteristics of patients vaccinated in the general population and those recruited into efficacy trials. Furthermore, the influenza vaccine may not contain the prevalent virus strain, and vaccine coverage may be suboptimal.

There are limited data on the effectiveness of influenza vaccination in patients with asthma or high-risk populations that included asthma. Six studies assessed the effectiveness of seasonal influenza vaccines, while one other studied the H1N1 pandemic vaccine (132).

In children, two retrospective cohort studies found that influenza vaccination was associated with a reduction in the rate of asthma exacerbations (133) and fewer acute respiratory problems (only in those less than 6 years of age) (134). A survey found that vaccination in children with asthma was associated with less use of rescue prednisolone (135), while a nested case-control study suggested that influenza vaccination was associated with fewer acute general practice visits for respiratory problems in children with long-term conditions (136). However, another case-control study suggested that vaccination was associated with an increased risk of unscheduled attendance for asthma care (137). In this study, the cases and controls were poorly balanced in terms of ethnicity and likelihood of vaccination in previous years. Although an adjusted analysis was undertaken, this may not have taken into account all the differences between the groups.

Only one study focused on adults with asthma (132). In this study, the H1N1 influenza vaccine was found to be protective against influenza in those aged under 61 years, but not in older patients. Also, it did not protect against AAE. Two other studies enrolled adults with long-term (136) or high-risk conditions (138); the first demonstrated a reduction in general practice visits, hospitalization and deaths from respiratory problems, while the second demonstrated a protective effect against influenza and influenza related hospitalization. Asthma was not analysed separately in these studies and it is thus not clear if influenza vaccination was beneficial for people with asthma.

A recent systematic review reports a 59-78% reduction in asthma attacks leading to emergency visits and/or hospitalizations after influenza vaccination and a vaccine effectiveness of 45% (95% CI 31 to 56) for laboratory-confirmed influenza in people with asthma based on a metaanalysis of two test-negative design case-control studies (139).

## **7. Safety of influenza vaccines in asthma**

Large retrospective and prospective studies have demonstrated the safety of influenza vaccines in children and adults with asthma, for both TIV and LAIV (131, 140-142). In these studies, vaccinated patients did not have more frequent asthma exacerbations than unvaccinated patients, and no other adverse event was more common in asthmatics. A study of adult asthma patients who reported bronchospasm after influenza vaccination, indicated that these symptoms were not related to vaccine hypersensitivity (143).

A common concern is the safety of egg-derived influenza vaccines in patients with egg-allergy, a frequent co-morbidity in children with asthma. The last case of anaphylaxis after influenza vaccination occurred more than 25 years ago at a time when the egg content of vaccines was much higher. The ovalbumin content of most current vaccines is less than 1.2 µg/mL, and an egg-free influenza vaccine is also available. Several studies demonstrated that influenza vaccines containing low levels of egg protein ( $\leq 1.2$  µg/mL) were safe even in egg-allergic patients (143-149). This also seemed to be true in egg-allergic patients with associated asthma. The recent SNIFFLE studies of LAIV in egg allergic children, including 634 children with asthma/recurrent wheeze (79.7% on daily inhaled corticosteroid treatment), found no immediate systemic allergic

reactions (150, 151). For 6.6% of children with asthma/recurrent wheeze, the parents reported wheeze within 72 hours of LAIV, but most wheeze episodes only required routine treatment; there was no hospitalization and no increase in respiratory symptoms in the four weeks after LAIV.

Based on the robust evidence that influenza vaccines are safe in asthma patients with and without egg allergy, British immunization guidelines (152) now recommend administration of LAIV in the community to children from 2 years of age, including those with asthma, irrespective of egg allergy, unless they have severe or acutely exacerbated asthma. US and Canadian guidelines remain more conservative and still suggest that vaccines containing egg proteins (e.g. LAIV) should not be used in children with egg allergy and/or asthma (153-155).

## **8. Antiviral treatment against influenza in patients with asthma**

For asthma patients with suspected influenza infection, treatment with antiviral medication as early as possible, prior to laboratory confirmation of influenza, is currently recommended (156-160). Since amantadine and rimantadine are limited by drug resistance, they have been replaced by neuraminidase inhibitors (NI). The currently marketed NIs are zanamivir and oseltamivir. However, post-marketing surveillance has revealed bronchospasm and worsening of lung function in a few cases when asthma patients were treated with zanamivir inhalation (161). Therefore, the manufacturer does now not recommend zanamivir for patients with chronic respiratory disease, including asthma (157, 158). Oseltamivir was not associated with any significant respiratory adverse effects and is recommended for treatment and chemoprophylaxis of influenza in children and adults with high-risk chronic conditions, including asthma (162-164). However, large-scale telephone surveys in the USA showed that having asthma, in contrast to diabetes, was not associated with increased rates of antiviral treatment of influenza cases (165).

Data on the efficacy of NI in asthma patients (162, 166-168) are limited. A benefit of oseltamivir treatment was found in children in an RCT that showed significantly improved pulmonary function and fewer AAEs (168). A meta-analysis, based on a single RCT, reported improved FEV1 after oral oseltamivir given to children with asthma and influenza infection, but no effects on peak flow or AAEs (169). Two recent systematic reviews found that oseltamivir relieved influenza symptoms in otherwise healthy children, but had no effect on children with asthma who have influenza-like illness (170, 171), a finding that is currently controversial.

As high rates of resistance limit the effectiveness of the currently available antiviral drugs, new NI (laninamivir, peramivir) and an RNA-dependent RNA polymerase inhibitor (favipiravir) are currently undergoing clinical trials (172). Laninamivir showed similar efficacy and safety to oseltamivir in the treatment of influenza in asthma patients (173).

## **9. Conclusions**

We observed significant variation in the reported rates of influenza detection among AAE episodes in both children and adults, with higher rates observed in the latter age group. This may be attributed to major differences in inclusion criteria, disease definitions, virus detection methodology, small population sizes and the limited number of available studies. Therefore, it is presently unclear to what degree influenza causes exacerbation of underlying asthma.

All European Union countries currently recommend influenza vaccination of people with asthma, with TIV being the most widely used vaccine. Nonetheless, vaccination

coverage varies between regions, and is significantly lower among children with asthma. Several factors and misbeliefs have been shown to predict non-adherence to influenza vaccination, while healthcare worker endorsement highly promotes vaccination. Major policy shifts and health campaigns may help in raising awareness and improve guideline implementation.

The limited immunogenicity data suggest that good seroprotection and seroconversion can be achieved in children and adults with asthma. However, higher vaccine doses may be required in elderly patients. Available studies suggest increased efficacy of LAIV in reducing influenza illness in children/adolescents with asthma compared to TIV, but do not provide evidence of efficacy of TIV in reducing influenza illness in asthmatics concurring with a recent systematic review (18).

There are some limited data to suggest that influenza vaccination reduces asthma-related morbidity in children in real-life settings, as has been concluded in another recent systematic review (139). The only data to suggest that vaccination may have a beneficial impact in adults with asthma are from studies of patients with long-term or high-risk conditions, not just asthma. The effectiveness outcomes of these studies are difficult to interpret due to lack of an agreed definition for asthma and/or influenza, and insufficient information on the type of vaccination used. Lack of randomization is also a limitation, as differences in the characteristics of those who do and do not receive the vaccine, such as disease severity and socioeconomic status, may independently impact on the likelihood of asthma morbidity, and analyses may not control for all these differences. Despite these limitations, population-based effectiveness studies are the only way to assess the impact of vaccination in real-life healthcare settings.

Inactivated influenza vaccines appear to be safe for people with asthma, and, provided they have low egg protein content ( $\leq 1.2 \mu\text{g/mL}$ ), also for those with egg allergy. LAIV is also safe in asthma and egg allergy with the exception of severe or acutely exacerbated asthma, where LAIV cannot be given. Oseltamivir is the NI that is currently used in asthma. Although it has moderately beneficial effects on influenza illness in healthy people, there are insufficient data to determine its efficacy and effectiveness in people with asthma. However, novel NIs are currently in development.

## **10. Recommendations and future needs**

People with asthma are at high risk of more severe forms of influenza, with increased hospitalization and admission at healthcare facilities, therefore:

- Education campaigns for both the general population and healthcare providers are needed to promote an increase in annual influenza vaccination, early case recognition and consideration of early empirical antiviral therapy, and to reduce influenza-attributable healthcare utilization among asthmatics.
- Large cohort and case control studies using standardized definitions (for AAE), sensitive influenza detection methods, such as PCR, and comprehensive assessment of respiratory pathogens are necessary in both children and adults with asthma.
- There is a need to develop more internationally co-ordinated registries, e.g. for Europe, that accurately collate vaccination status along with medical and socio-demographic details to assess the impact of public health interventions over time.
- Multiple sources of data must be used to record vaccination status (e.g. self-reported as well as medical notes, vaccination card or billing data).

- Targeted vaccination of children and at-risk groups is needed.
- Further studies of influenza vaccine immunogenicity, comparing healthy and asthmatic populations, are required to determine if people with asthma have normal influenza vaccine responses or if they require influenza vaccines with enhanced immunogenicity. The discovery and development of improved immune correlates of protection against influenza will enable more meaningful testing of vaccine immunogenicity.
- In view of the uncertainty around the degree of protection that influenza vaccination affords in people of all ages with asthma, further efficacy data need to be collected in this population. Data should be stratified by age and asthma severity, using adequately powered, randomised, placebo-controlled trials that compare both TIV and LAIV to non-vaccinated controls.
- Further studies are needed to evaluate the effectiveness of influenza vaccination in patients with asthma, but must be designed to minimize any risk of bias.
- Safety data in asthma with and without egg allergy are required for new influenza vaccines, and, depending on egg protein content, for new LAIV batches.
- There is a need to collect more safety data on zanamivir in patients with chronic respiratory disease, and efficacy data on oseltamivir in children with asthma.
- Development and testing of new anti-influenza drugs among asthmatics is needed.

## References

1. Global Atlas of Asthma. Published by the European Academy of Allergy and Clinical Immunology. Editors: Cezmi A. Akdis, Ioana Agache, 2013.
2. ERS: The European Lung White Book 2003.
3. Darveaux JI, Lemanske RF. Infection-Related Asthma. *Journal of Allergy and Clinical Immunology: In Practice* 2014;**2**(6):658-663.
4. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. *Nature Reviews Microbiology* 2012; **10**(7):459-471.
5. Gern JE. The ABCs of rhinoviruses, wheezing, and asthma. *J Virol* 2010;**84**(15):7418-7426.
6. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee W-M, et al. Evidence for a Causal Relationship between Allergic Sensitization and Rhinovirus Wheezing in Early Life. *Am J Respir Crit Care Med* 2012;**185**(3):281-285.
7. Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, et al. Viruses and bacteria in acute asthma exacerbations - A GA2LEN-DARE\* systematic review. *Allergy* 2010;**66**(4):458-468.
8. Thomas AO, Lemanske RF, Jr., Jackson DJ. Infections and their role in childhood asthma inception. *Pediatr Allergy Immunol* 2014;**25**(2):122-128.
9. Wennergren G. Impact of viral infection on bronchial hyperresponsiveness. *Pediatr Allergy Immunol* 1996;**7**(9 Suppl):10-13.
10. Kava T. Effect of respiratory infections on exacerbation of asthma in adult patients. A six-month follow-up. *Allergy* 1986;**41**(8):556-561.
11. Busse WW. Role and contribution of viral respiratory infections to asthma. *Allergy* 1993;**48**(17 Suppl):57-61; discussion 62-54.

12. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study. *PLoS Med* 2013;**10**(11):e1001558.
13. Thompson WW. Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. *JAMA* 2003;**289**(2):179.
14. Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur RE, Johansen H, et al. The effect of universal influenza immunization on mortality and health care use. *PLoS Med* 2008;**5**(10):e211.
15. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. *Scand J Immunol* 2004;**59**(1):1-15.
16. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The underrecognized burden of influenza in young children. *N Engl J Med* 2006;**355**(1):31-40.
17. Neuzil KM, Mellen BG, Wright PF, Mitchel Jr EF, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. *N Engl J Med* 2000;**342**(4):225-231.
18. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. *Cochrane Database of Systematic Reviews* 2013;**2**:CD000364.
19. Bassetti M, Parisini A, Calzi A, Pallavicini FM, Cassola G, Artioli S, et al. Risk factors for severe complications of the novel influenza A (H1N1): analysis of patients hospitalized in Italy. *Clin Microbiol Infect* 2011;**17**(2):247-250.
20. Canak G, Kovacevic N, Vukadinov J, Turkulov V, Sevic S, Doder R, et al. Clinical features, treatments and outcomes of influenza A (H1N1) 2009 among the hospitalized patients in the Clinic for Infectious Diseases in Novi Sad. *Vojnosanit Pregl* 2013;**70**(2):155-162.
21. Celjuska-Tosev E, Kuzman I, Drazenovic V, Knezovic I, Civljak R. Clinical and epidemiological characteristics of hospitalized patients with pandemic a(H1N1) 2009 influenza. *Infektoloski Glasnik* 2010;**30**(4):149-159.
22. Cutter JL, Ang LW, Lai FYL, Subramony H, Ma S, James L. Outbreak of pandemic influenza a (H1N1-2009) in Singapore, May to September 2009. *Annals of the Academy of Medicine Singapore* 2010;**39**(4):273-282.
23. Al-Khuwaitir TS, Al-Abdulkarim AS, Abba AA, Yousef AM, El-Din MA, Rahman KT, et al. H1N1 influenza A: Preliminary evaluation in hospitalized patients in a secondary care facility in Saudi Arabia. *Saudi Med J* 2009;**30**(12):1532-1536.
24. Fleege L, Hallberg E, Morin C, Danila R, Lynfield R. Novel H1N1 influenza hospitalizations: Minneapolis-St. Paul metropolitan area, 2008-2009. *Minn Med* 2009;**92**(11):38-42.
25. Gonzalez-Velez AE, Diaz-Agero-Perez C, Robustillo-Rodela A, Cornejo-Gutierrez AM, Pita-Lopez MJ, Oliva-Iniguez L, et al. Factors associated to admission to Intensive Care in patients hospitalized due to pandemic Influenza A/H1N1 2009. *Med Intensiva* 2011;**35**(8):463-469.
26. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. *N Engl J Med* 2009;**361**(20):1935-1944.
27. Lucker LM, Kherad O, Iten A, Wagner N, Descombes M, Camus V, et al. Clinical features and outcome of hospitalised adults and children with the 2009 influenza A H1N1 infection at Geneva's University Hospital. *Swiss Med Wkly* 2011;**141**:w13177.
28. Myles P, Nguyen-Van-Tam JS, Semple MG, Brett SJ, Bannister B, Read RC, et al. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. *Eur Respir J* 2013;**41**(4):824-831.
29. Nguyen-Van-Tam JS, Openshaw PJM, Hashim A, Gadd EM, Lim WS, Semple MG, et al. Risk factors for hospitalisation and poor outcome with pandemic

- A/H1N1 influenza: United Kingdom first wave (May-September 2009). *Thorax* 2010;**65**(7):645-651.
30. Pecavar B, Nadrah K, Papst L, Cec V, Kotar T, Maticic M, et al. Clinical characteristics of adult patients with influenza-like illness hospitalized in general ward during Influenza A H1N1 pandemic 2009/2010. *Wiener Klinische Wochenschrift* 2011;**123**(21-22):662-667.
  31. Rodriguez-Rieiro C, Carrasco-Garrido P, Hernandez-Barrera V, Lopez de Andres A, Jimenez-Trujillo I, Gil de Miguel A, et al. Pandemic influenza hospitalization in Spain (2009): incidence, in-hospital mortality, comorbidities and costs. *Hum Vaccin Immunother* 2012;**8**(4):443-447.
  32. Zarogoulidis P, Kouliatsis G, Papanas N, Spyrtos D, Constantinidis TC, Kouroumichakis I, et al. Long-term respiratory follow-up of H1N1 infection. *Virology* 2011;**8**:319.
  33. McKenna JJ, Bramley AM, Skarbinski J, Fry AM, Finelli L, Jain S, et al. Asthma in patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection-United States, 2009. *BMC Infect Dis* 2013;**13**:57.
  34. Djordjevic Z, Canovic P, Todorovic Z, Gajovic O, Mijailovic Z, Popovska B. Characteristics of influenza a (H1N1): Analysis of the cases treated in clinical centre "kragujevac" in Kragujeva. *Medicinski Casopis* 2011;**45**(4):15-20.
  35. Centers for Disease C, Prevention. Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009. *MMWR - Morbidity & Mortality Weekly Report* 2010;**58**(51):1436-1440.
  36. Dawood FS, Fiore A, Kamimoto L, Bramley A, Reingold A, Gershman K, et al. Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. *J Pediatr* 2010;**157**(5):808-814.
  37. Desmoulins C, Michard-Lenoir AP, Naud J, Claudet I, Nouyrigat V, Cheron G. Clinical features and outcome of 2009 H1N1 influenza in the pediatric setting. Multicenter prospective study in the ED. *Arch Pediatr* 2011;**18**(5):505-511.
  38. Bue M, Chevallier J, Pigeon Kherchiche P. Clinical study of a cohort of 94 children with influenza A(H1N1) on the Reunion Island. *Bull Soc Pathol Exot* 2011;**104**(2):135-141.
  39. Chiu SS, Chan KH, Chen H, Young BW, Lim W, Wong WH, et al. Virologically confirmed population-based burden of hospitalization caused by influenza A and B among children in Hong Kong. *Clin Infect Dis* 2009;**49**(7):1016-1021.
  40. Chiu SS, Lau YL, Chan KH, Wong WH, Peiris JS. Influenza-related hospitalizations among children in Hong Kong. *N Engl J Med* 2002;**347**(26):2097-2103.
  41. Weigl JA, Puppe W, Schmitt HJ. The incidence of influenza-associated hospitalizations in children in Germany. *Epidemiol Infect* 2002;**129**(3):525-533.
  42. Katsunuma T, Matsui T, Iwata T, Nambu M, Kondo N. Hospitalizations associated with pandemic influenza A (H1N1) 2009 in asthmatic children in Japan. *Allergology International* 2012;**61**(1):75-82.
  43. Al Subaie SS, Al Saadi MA. Features associated with severe disease in hospitalized children with 2009 influenza A (H1N1) infection at a university hospital in Riyadh, Saudi Arabia. *Ann Saudi Med* 2012;**32**(1):53-58.
  44. Chong CY, Tan NW, Menon A, Thoon KC, Tee NW, Fu S. Risk Factors for Complicated Influenza A (H1N1) 2009 Disease in Children. *Ann Acad Med Singapore* 2013;**42**(5):232-236.
  45. Mansour MM, Al Hadidib KM. 2009 H1N1 influenza A in children: a descriptive clinical study. *Ann Saudi Med* 2012;**32**(1):59-63.
  46. Silvennoinen H, Peltola V, Vainionpaa R, Ruuskanen O, Heikkinen T. Admission diagnoses of children 0-16 years of age hospitalized with influenza. *Eur J Clin Microbiol Infect Dis* 2012;**31**(3):225-231.

47. Tasar MA, Dallar Y, Soyer OU, Yildirim S, Tasar M, Arikan FI. Risk factors and prognosis in children hospitalized due to pandemic H1N1 influenza A virus infection in Ankara, Turkey. *Turkish Journal of Medical Sciences* 2012;**42**(3):433-440.
48. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med* 2000;**342**(4):232-239.
49. Dawood FS, Chaves SS, Perez A, Reingold A, Meek J, Farley MM, et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. *J Infect Dis* 2014;**209**(5):686-694.
50. Dawood FS, Kamimoto L, D'Mello TA, Reingold A, Gershman K, Meek J, et al. Children with asthma hospitalized with seasonal or pandemic influenza, 2003-2009. *Pediatrics* 2011;**128**(1):e27-e32.
51. O'Riordan S, Barton M, Yau Y, Read SE, Allen U, Tran D. Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. *CMAJ Canadian Medical Association Journal* 2010;**182**(1):39-44.
52. Chiu SS, Chan KH, Wong WH, Chan EL, Peiris JS. Age-matched comparison of children hospitalized for 2009 pandemic H1N1 influenza with those hospitalized for seasonal H1N1 and H3N2. *PLoS ONE [Electronic Resource]* 2011;**6**(7):e21837.
53. Song X, DeBiasi RL, Campos JM, Fagbuyi DB, Jacobs BR, Singh N. Comparison of pandemic and seasonal influenza A infections in pediatric patients: were they different? *Influenza Other Respi Viruses* 2012;**6**(1):25-27.
54. Miller AC, Safi F, Hussain S, Subramanian RA, Elamin EM, Sinert R. Novel influenza A(H1N1) virus among gravid admissions. *Arch Intern Med* 2010;**170**(10):868-873.
55. Miller AC, Subramanian RA, Safi F, Sinert R, Zehtabchi S, Elamin EM. Influenza A 2009 (H1N1) virus in admitted and critically ill patients. *J Intensive Care Med* 2012;**27**(1):25-31.
56. Michaan N, Amzallag S, Laskov I, Cohen Y, Fried M, Lessing JB, et al. Maternal and neonatal outcome of pregnant women infected with H1N1 influenza virus (swine flu). *J Matern Fetal Neonatal Med* 2012;**25**(2):130-132.
57. Taha I. Characteristics of pregnant Women admitted with 2009 H1N1 Influenza in a referral maternity hospital at Al-Madinah, Saudi Arabia. *Egyptian Journal of Hospital Medicine (July 2013)* 2014;**52**:650-657.
58. Cullen G, Martin J, O'Donnell J, Boland M, Canny M, Keane E, et al. Surveillance of the first 205 confirmed hospitalised cases of pandemic H1N1 influenza in Ireland, 28 April - 3 October 2009. *Euro surveillance: European communicable disease bulletin* 2009;**14**(44):429-433.
59. Gilca R, De Serres G, Boulianne N, Ouhoumane N, Papenburg J, Douville-Fradet M, et al. Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. *Influenza Other Respi Viruses* 2011;**5**(4):247-255.
60. Lee TC, Taggart LR, Mater B, Katz K, McGeer A. Predictors of pandemic influenza infection in adults presenting to two urban emergency departments, Toronto, 2009. *CJEM Canadian Journal of Emergency Medical Care* 2011;**13**(1):7-12.
61. Shimoni Z, Niven M, Kama N, Dusseldorp N, Froom P. Increased complaints of fever in the emergency room can identify influenza epidemics. *Eur J Intern Med* 2008;**19**(7):494-498.
62. Crisinel PA, Barazzone C, Kaiser L, L'Huillier AG, Taguebue J, Wagner N, et al. Comparison of clinical presentation of respiratory tract infections in H1N1/09-positive and H1N1/09-negative patients. *Eur J Pediatr* 2012;**171**(1):159-166.
63. Miller EK, Griffin MR, Edwards KM, Weinberg GA, Szilagyi PG, Staat MA, et al. Influenza burden for children with asthma. *Pediatrics* 2008;**121**(1):1-8.



64. Leckerman KH, Sherman E, Knorr J, Zaoutis TE, Coffin SE. Risk factors for healthcare-associated, laboratory-confirmed influenza in hospitalized pediatric patients: a case-control study. *Infect Control Hosp Epidemiol* 2010;**31**(4):421-424.
65. Libster R, Coviello S, Cavalieri ML, Morosi A, Alabart N, Alvarez L, et al. Pediatric hospitalizations due to influenza in 2010 in Argentina. *N Engl J Med* 2010;**363**(25):2472-2473.
66. Lee MC, Kim HY, Kong SG, Kim YM, Park SE, Im YT, et al. Clinical characteristics of pandemic influenza A (H1N1) 2009 pediatric infection in Busan and Gyeongsangnam-do: One institution. *Tuberculosis and Respiratory Diseases* 2012;**72**(6):493-500.
67. Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza, 2003. *Am J Prev Med* 2009;**36**(4):292-296.
68. Torres SF, Iolster T, Schnitzler EJ, Farias JA, Bordogna AC, Rufach D, et al. High mortality in patients with influenza A pH1N1 2009 admitted to a pediatric intensive care unit: a predictive model of mortality. *Pediatr Crit Care Med* 2012;**13**(2):e78-83.
69. Libster R, Bugna J, Coviello S, Hijano DR, Dunaiewsky M, Reynoso N, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. *N Engl J Med* 2010;**362**(1):45-55.
70. Okada T, Morozumi M, Matsubara K, Komiyama O, Ubukata K, Takahashi T, et al. Characteristic findings of pediatric inpatients with pandemic (H1N1) 2009 virus infection among severe and nonsevere illnesses. *Journal of Infection and Chemotherapy* 2011;**17**(2):238-245.
71. Jiang H, Yu D, Ruan F, Xu W, Huang T, Li L, et al. Clinical characteristics of adult influenza inpatients in ten provinces in China and analysis of severe risk factors. *Zhonghua liuxingbingxue zazhi* 2015;**36**(3):216-221.
72. Wark PAB, Johnston SL, Moric I, Simpson JL, Hensley MJ, Gibson PG. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. *Eur Respir J* 2001;**19**(1):68-75.
73. Atmar RL, Guy E, Guntupalli KK, Zimmerman JL, Bandi VD, Baxter BD, et al. Respiratory Tract Viral Infections in Inner-City Asthmatic Adults. *Arch Intern Med* 1998;**158**(22):2453.
74. Simpson JL, Moric I, Wark PA, Johnston SL, Gibson PG. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques. *J Clin Virol* 2003;**26**(3):339-346.
75. Azevedo AM, Durigon EL, Okasima V, Queiroz DA, de Moraes-Vasconcelos D, Duarte AJ, et al. Detection of influenza, parainfluenza, adenovirus and respiratory syncytial virus during asthma attacks in children older than 2 years old. *Allergol Immunopathol (Madr)* 2003;**31**(6):311-317.
76. Iikura M, Hojo M, Koketsu R, Watanabe S, Sato A, Chino H, et al. The importance of bacterial and viral infections associated with adult asthma exacerbations in clinical practice. *PLoS One* 2015;**10**(4):e0123584.
77. Teichtahl H, Buckmaster N, Pertnikovs E. The Incidence of Respiratory Tract Infection in Adults Requiring Hospitalization for Asthma. *Chest* 1997;**112**(3):591-596.
78. Tan WC, Xiang X, Qiu D, Ng TP, Lam SF, Hegele RG. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. *The American Journal of Medicine* 2003;**115**(4):272-277.
79. Johnston NW, Johnston SL, Duncan JM, Greene JM, Keadze T, Keith PK, et al. The September epidemic of asthma exacerbations in children: A search for etiology. *J Allergy Clin Immunol* 2005;**115**(1):132-138.
80. Khetsuriani N, Kazerouni NN, Erdman DD, Lu X, Redd SC, Anderson LJ, et al. Prevalence of viral respiratory tract infections in children with asthma. *J Allergy Clin Immunol* 2007;**119**(2):314-321.

81. Bueving HJ, Bernsen RMD, de Jongste JC, van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADM, et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. *Am J Respir Crit Care Med* 2004;**169**(4):488-493.
82. Mandelcwaig A, Moulin F, Menager C, Rozenberg F, Lebon P, Gendrel D. Underestimation of influenza viral infection in childhood asthma exacerbations. *J Pediatr* 2010;**157**(3):505-506.
83. Thumerelle C, Deschildre A, Bouquillon C, Santos C, Sardet A, Scalbert M, et al. Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: A prospective study in the Nord-Pas de Calais region (France). *Pediatr Pulmonol* 2003;**35**(2):75-82.
84. Vallet C, Pons-Catalano C, Mandelcwaig A, Wang A, Raymond J, Lebon P, et al. Human Bocavirus: A Cause of Severe Asthma Exacerbation in Children. *J Pediatr* 2009;**155**(2):286-288.
85. Kloepper KM, Olenec JP, Lee WM, Liu G, Vrtis RF, Roberg KA, et al. Increased H1N1 Infection Rate in Children with Asthma. *Am J Respir Crit Care Med* 2012;**185**(12):1275-1279.
86. Biscardi S, Lorrot M, Marc E, Moulin F, Boutonnat-Faucher B, Heilbronner C, et al. Mycoplasma pneumoniae and Asthma in Children. *Clin Infect Dis* 2004;**38**(10):1341-1346.
87. Greenhawt MJ. Influenza vaccination in asthmatic patients. *J Allergy Clin Immunol* 2014;**133**(4):1233-1234.e1233.
88. O'Flanagan, D, Cotter, S, Mereckiene, J. Seasonal influenza vaccination in EU / EEA, influenza season 2011-12, VENICE II Consortium. 1–67, 2013.
89. Centre for Disease Control and Prevention. Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices — United States 2013–2014. *MMWR* 2014;**62**:1-48.
90. Public Health England. Influenza: the green book. Immun. against Infect. Dis. 185–218. Public Health England, 2014.
91. Esposito S, Marchisio P, Droghetti R, Lambertini L, Faelli N, Bosis S, et al. Influenza vaccination coverage among children with high-risk medical conditions. *Vaccine* 2006;**24**(24):5251-5255.
92. Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, de Andrés AL, de Miguel Díez J, de Miguel ÁG. Coverage and Predictors of Adherence to Influenza Vaccination among Spanish Children and Adults with Asthma. *Infection* 2009;**38**(1):52-57.
93. Lopez-de-Andres A, Carrasco-Garrido P, Hernandez-Barrera V, de Miguel AG, Jimenez-Garcia R. Coverages and factors associated with influenza vaccination among subjects with chronic respiratory diseases in Spain. *Eur J Public Health* 2008;**18**(2):173-177.
94. Mayo Montero E, Hernández-Barrera V, Carrasco-Garrido P, Gil de Miguel Á, Jiménez-García R. Influenza vaccination among persons with chronic respiratory diseases: Coverage, related factors and time-trend, 1993–2001. *Public Health* 2007;**121**(2):113-121.
95. Santos-Sancho JM, López-de Andrés A, Jimenez-Trujillo I, Hernández-Barrera V, Carrasco-Garrido P, Astasio-Arbiza P, et al. Adherence and factors associated with influenza vaccination among subjects with asthma in Spain. *Infection* 2013;**41**(2):465-471.
96. Keenan H, Campbell J, Evans PH. Influenza vaccination in patients with asthma: why is the uptake so low? *Br J Gen Pract* 2007;**57**(538):359-363.
97. Leo HL, Clark SJ, Butchart AT, Singer DC, Clark NM, Davis MM. 2009 Seasonal and H1N1 influenza vaccination compliance in asthmatic children and adults. *J Allergy Clin Immunol* 2010;**126**(1):166-168.

98. Vázquez-Fernández del Pozo S, Hernández-Barrera V, Carrasco-Garrido P, Alvarez-Martín E, López-de Andrés A, Gil de Miguel A, et al. Influenza vaccination coverage and related factors among Spanish children. *J Infect* 2007;**54**(5):483-489.
99. Rance F, Chave C, De Blic J, Deschildre A, Donato L, Dubus J, et al. Low influenza vaccination coverage in asthmatic children in France in 2006-7. *Euro Surveillance: European Communicable Disease Bulletin* 2008;**13**(43):23.
100. Centre for Disease Control and Prevention. Vaccination Coverage Among Persons with Asthma — United States 2010–2011 Influenza Season. *MMWR* 2013;**62**:973–978.
101. Dower J, Donald M, Begum N, Vlack S, Ozolins I. Patterns and determinants of influenza and pneumococcal immunisation among adults with chronic disease living in Queensland, Australia. *Vaccine* 2011;**29**(16):3031-3037.
102. Figaro MK, Belue R. Prevalence of Influenza Vaccination in a High-risk Population. *J Ambul Care Manage* 2005;**28**(1):24-29.
103. Foty RG, Guttman A, Kwong JC, Maaten S, Manuel D, Stieb DM, et al. Predictors of universal influenza vaccination uptake in grades 1 and 2 Toronto school children: Effective vaccination strategies should not end with at risk children. *Vaccine* 2010;**28**(39):6518-6522.
104. Lu P-j, Callahan DB, Ding H, Euler GL. Influenza A (H1N1) 2009 Monovalent Vaccination Among Adults with Asthma, U.S., 2010. *Am J Prev Med* 2011;**41**(6):619-626.
105. Lu P-j, Euler GL, Callahan DB. Influenza Vaccination Among Adults with Asthma. *Am J Prev Med* 2009;**37**(2):109-115.
106. Tuppin P, Samson S, Weill A, Ricordeau P, Allemand H. Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009. *Vaccine* 2011;**29**(28):4632-4637.
107. Vozoris NT, Loughheed MD. Influenza vaccination among Canadians with chronic respiratory disease. *Respir Med* 2009;**103**(1):50-58.
108. Walter EB, Hellkamp AS, Goldberg KC, Montgomery D, Patterson B, Dolor R. Improving influenza vaccine coverage among asthmatics: a practice-based research network study. *JCOM* 2008;**15**(5):227-234.
109. Buyuktiryaki B, Soyer OU, Erkocoglu M, Dogan A, Azkur D, Kocabas CN, et al. What a pandemic teaches us about vaccination attitudes of parents of children with asthma. *Vaccine* 2014;**32**(20):2275-2280.
110. Gnanasekaran SK, Finkelstein JA, Lozano P, Farber HJ, Chi FW, Lieu TA. Influenza Vaccination Among Children With Asthma in Medicaid Managed Care. *Ambul Pediatr* 2006;**6**(1):1-7.
111. Lyn-Cook R, Halm EA, Wisnivesky JP. Determinants of adherence to influenza vaccination among inner-city adults with persistent asthma. *Primary Care Respiratory Journal* 2007;**16**(4):229-235.
112. Soyer OU, Hudaverdiyev S, Civelek E, Isik E, Karabulut E, Kocabas C, et al. Parental perspectives on influenza vaccination in children with asthma. *Pediatr Pulmonol* 2010;**46**(2):139-144.
113. Bueving HJ, Thomas S, Wouden JCvd. Is influenza vaccination in asthma helpful? *Curr Opin Allergy Clin Immunol* 2005;**5**(1):65-70.
114. Fleming DM, Monto AS. Influenza Vaccination in Children with Asthma. *Am J Respir Crit Care Med* 2005;**171**(8):931-931.
115. Clark SJ, Cowan AE, Wortley PM. Perspectives of Allergists/Immunologists on the 2009–2010 H1N1 Vaccination Effort. *J Asthma* 2012;**49**(2):184-189.
116. Dombkowski KJ, Leung SW, Clark SJ. Physician Perspectives Regarding Annual Influenza Vaccination Among Children With Asthma. *Ambul Pediatr* 2008;**8**(5):294-299.

117. Lopez-de-Andres A, Hernández-Barrera V, Carrasco-Garrido P, Gil-de-Miguel Á, Jiménez-García R. Influenza vaccination coverage among Spanish children, 2006. *Public Health* 2009;**123**(7):465-469.
118. Paul IM, Eleoff SB, Shaffer ML, Bucher RM, Moyer KM, Gusic ME. Improving Influenza Vaccination Rates for Children Through Year-round Scheduling. *Ambul Pediatr* 2006;**6**(4):230-234.
119. Teufel RJ, Basco WT, Simpson KN. Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. *J Hosp Med* 2008;**3**(2):134-141.
120. Trogdon JG, Nurmagambetov TA, Thompson HF. The Economic Implications of Influenza Vaccination for Adults with Asthma. *Am J Prev Med* 2010;**39**(5):403-410.
121. Bae EY, Choi UY, Kwon HJ, Jeong DC, Rhim JW, Ma SH, et al. Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing. *Clinical & Vaccine Immunology: CVI* 2013;**20**(6):811-817.
122. Pedroza A, Huerta JG, de la Luz Garcia M, Rojas A, López-Martínez I, Penagos M, et al. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. *Int J Infect Dis* 2009;**13**(4):469-475.
123. Zuccotti G, Amendola A, Vigano A, Pariani E, Zappa A, Pogliani L, et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. *Vaccine* 2007;**25**(37-38):6692-6698.
124. Busse WW, Peters SP, Fenton MJ, Mitchell H, Bleecker ER, Castro M, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. *J Allergy Clin Immunol* 2011;**127**(1):130-137, 137.e131-133.
125. Abadoglu O, Mungan D, Pasaoglu G, Celik G, Misirligil Z. Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations. *J Asthma* 2004;**41**(3):279-283.
126. Bueving HJ, van der Wouden JC, Raat H, Bernsen RM, de Jongste JC, van Suijlekom-Smit LW, et al. Influenza vaccination in asthmatic children: effects on quality of life and symptoms. *Eur Respir J* 2004;**24**(6):925-931.
127. Fayyaz Jahani F, Karramyyar M, Ahmadnezhad E. Inactivated-trivalent influenza vaccination in asthmatic under-5 children: A randomized double-blind placebo trial. *Arch Dis Child* 2012;**97**:A516.
128. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. *Pediatr Infect Dis J* 2006;**25**(10):860-869.
129. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. *Pediatr Infect Dis J* 2006;**25**(10):870-879.
130. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med* 2007;**356**(7):685-696.
131. Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. *Eur J Clin Microbiol Infect Dis* 2012;**31**(10):2549-2557.
132. Koshio N, Hasegawa T, Suzuki K, Tanabe Y, Koya T, Sakagami T, et al. Analysis of the influenza A (H1N1) 2009 pandemic infection in Japanese asthmatic patients: using a questionnaire-based survey. *Allergology International* 2014;**63**(1):67-74.
133. Kramarz P, Destefano F, Gargiullo PM, Chen RT, Lieu TA, Davis RL, et al. Does influenza vaccination prevent asthma exacerbations in children? *J Pediatr* 2001;**138**(3):306-310.

134. Smits AJ, Hak E, Stalman WAB, van Essen GA, Hoes AW, Verheij TJM. Clinical effectiveness of conventional influenza vaccination in asthmatic children. *Epidemiol Infect* 2002;**128**(2):205-211.
135. Ong BA, Forester J, Fallot A. Does influenza vaccination improve pediatric asthma outcomes? *J Asthma* 2009;**46**(5):477-480.
136. Hak E. Clinical Effectiveness of Influenza Vaccination in Persons Younger Than 65 Years With High-Risk Medical Conditions. *Arch Intern Med* 2005;**165**(3):274.
137. Christy C, Aligne C, Auinger P, Pulcino T, Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. *Arch Dis Child* 2004;**89**(8):734-735.
138. Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, et al. Influenza vaccine effectiveness among 50–64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003–2004. *Vaccine* 2007;**25**(1):154-160.
139. Vasiliou E. et al Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. *Clin Infect Dis*. *In press*.
140. Castro M, Dozor A, Fish J, Irvin C, Scharf S, Scheipeter ME, et al. The safety of inactivated influenza vaccine in adults and children with asthma. *N Engl J Med* 2001;**345**(21):1529-1536.
141. Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. *Vaccine* 2012;**30**(19):2989-2998.
142. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. *Pediatr Infect Dis J* 2008;**27**(5):444-452.
143. Miller RL, Cheng M, DiMango EA, Geromanos K, Rothman PB, American Lung Association Asthma Clinical Research C. T-cell responses and hypersensitivity to influenza and egg antigens among adults with asthma immunized with the influenza vaccine. *J Allergy Clin Immunol* 2003;**112**(3):606-608.
144. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. *Pediatrics* 2010;**125**(5):e1024-e1030.
145. Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. *J Allergy Clin Immunol* 2010;**126**(2):317-323.
146. Greenhawt MJ, Spergel JM, Rank MA, Green TD, Masnoor D, Sharma H, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. *Annals of Allergy, Asthma & Immunology* 2012;**109**(6):426-430.
147. Howe LE, Conlon ASC, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. *Annals of Allergy, Asthma and Immunology* 2011;**106**(5):446-447.
148. Esposito S, Gasparini C, Martelli A, Zenga A, Tremolati E, Varin E, et al. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. *Vaccine* 2008;**26**(36):4664-4668.
149. Greenhawt MJ, Chernin AS, Howe L, Li JT, Sanders G. The safety of the H1N1 influenza A vaccine in egg allergic individuals. *Annals of Allergy, Asthma & Immunology* 2010;**105**(5):387-393.
150. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. *BMJ* 2015:h6291.
151. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, Investigators SS. Safety of live attenuated influenza vaccine in atopic children with egg allergy. *J Allergy Clin Immunol* 2015;**136**(2):376-381.

152. The Green Book- Immunisation against infectious disease. Chapter 19 – Influenza, 2014. <https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19>.
153. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on immunization practices, United States, 2015-16 influenza season. *MMWR Morb Mortal Wkly Rep* 2015;**64**(30):818-825.
154. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2014-2015. <http://www.phac-aspc.gc.ca/naci-ccni/assets/pdf/flu-grippe-eng.pdf>.
155. Children's flu vaccine. National Health System (NHS) website: <http://www.nhs.uk/conditions/vaccinations/pages/child-flu-vaccine.aspx>.
156. Nathan RA, Geddes D, Woodhead M. Management of influenza in patients with asthma or chronic obstructive pulmonary disease. *Annals of Allergy, Asthma & Immunology* 2001;**87**(6):447-454.
157. Aoki FY, Allen UD, Stiver HG, Evans GA. The use of antiviral drugs for influenza: A foundation document for practitioners. *Canadian Journal of Infectious Diseases and Medical Microbiology* 2013;**24**(3):1C-15C.
158. Aoki FY, Allen UD, Stiver HG, Evans GA. The Use of Antiviral Drugs for Influenza: Guidance for Practitioners 2012/2013. *Canadian Journal of Infectious Diseases and Medical Microbiology* 2012;**23**(4):e79-e92.
159. Rank MA, Li JT. Clinical pearls for preventing, diagnosing, and treating seasonal and 2009 H1N1 influenza infection in patients with asthma. *J Allergy Clin Immunol* 2009;**124**(5):1123-1126.
160. Sandrock CE, Norris A. Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome. *Clin Rev Allergy Immunol* 2014;**48**(1):104-113.
161. McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: Zanamivir and oseltamivir. *Ann Pharmacother* 2001;**35**(1):57-70.
162. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. *Curr Med Res Opin* 2006;**22**(1):75-82.
163. Williamson JC, Pegram PS. Neuraminidase inhibitors in patients with underlying airways disease. *Am J Respir Med* 2002;**1**(2):85-90.
164. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. *J Antimicrob Chemother* 2010;**65**(Supplement 2):ii11-ii24.
165. Biggerstaff M, Jhung MA, Reed C, Fry AM, Balluz L, Finelli L. Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010-2011 influenza season-United States. *J Infect Dis* 2014;**210**(4):535-544.
166. Cass LM, Gunawardena KA, Macmahon MM, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. *Respir Med* 2000;**94**(2):166-173.
167. Gravenstein S, Johnston SL, Loeschel E, Webster A. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. *Drug Saf* 2001;**24**(15):1113-1125.
168. Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. *Pediatr Infect Dis J* 2005;**24**(3):225-232.
169. Shun-Shin M, Thompson M, Heneghan C, Perera R, Hamden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: Systematic review and meta-analysis of randomised controlled trials. *BMJ (Online)* 2009;**339**(7718):449.
170. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. *BMJ (Online)* 2014;**348**(g2545).

171. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews* 2014;**4**:CD008965.
172. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, et al. Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk Patients. *Antimicrob Agents Chemother* 2011;**55**(6):2803-2812.
173. Watanabe A. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. *Journal of Infection and Chemotherapy* 2013;**19**(1):89-97.
174. Chacon R, Mirza S, Rodriguez D, Paredes A, Guzman G, Moreno L, et al. Demographic and clinical characteristics of deaths associated with influenza A (H1N1) pdm09 in Central America and Dominican Republic 2009–2010. *BMC Public Health* 2015;**15**(1):734.
175. Hagerman A, Posfay Barbe KM, Duppenenthaler A, Heininger U, Berger C, The PISG. Clinical characteristics and outcomes in children hospitalised with pandemic influenza A/H1N1/09 virus infection—a nationwide survey by the Pediatric Infectious Diseases Group of Switzerland. *Swiss Med Wkly* 2015;**145**:w14171.
176. Kwon J-M, Shim JW, Kim DS, Jung HL, Park MS, Shim JY. Prevalence of respiratory viral infection in children hospitalized for acute lower respiratory tract diseases, and association of rhinovirus and influenza virus with asthma exacerbations. *Korean J Pediatr* 2014;**57**(1):29-34.
177. Park YB, Yoo KHA, Hwang YI, Lee WY, Lee CL. Asthma and severity of the 2009 novel H1N1 influenza: A case-control study. *Respirology* 2013;**18**:152.
178. Placzek HE, Madoff LC. Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. *Am J Public Health* 2014;**104**(11):e118-e125.
179. Stripeli F, Logotheti I, Vraila VM, Balta C, Patsioura A, Papaevangelou V, et al. Pandemic influenza A vs seasonal influenza A in hospitalized children in Athens. *Paediatrics and International Child Health* 2015;**35**(1):61-64.
180. Tam K, Yousey-Hindes K, Hadler JL. Influenza-related hospitalization of adults associated with low census tract socioeconomic status and female sex in New Haven County, Connecticut, 2007-2011. *Influenza Other Respir Viruses* 2014;**8**(3):274-281.
181. Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014–15 influenza season. *MMWR Morb Mortal Wkly Rep* 2014;**63**(32):691-697.
182. Byington CL, Barnett ED, Davies HD, Edwards KM, Jackson MA, Maldonado YA, et al. Recommendations for Prevention and Control of Influenza in Children, 2014–2015. *Pediatrics* 2014;**134**(5):e1503-e1519.
183. Pennant KN, Costa JJ, Fuhlbrigge AL, Sax PE, Szent-Gyorgyi LE, Coblyn J, et al. Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices. In: Open forum infectious diseases; 2015: Oxford University Press; 2015. p. ofv119.
184. Gnatiuc L, Buist AS, Kato B, Janson C, Ait-Khaled N, Nielsen R, et al. Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites. *Int J Tuberc Lung Dis* 2015;**19**(1):21-30.
185. Vernacchio L, Francis ME, Epstein DM, Santangelo J, Trudell EK, Reynolds ME, et al. Effectiveness of an asthma quality improvement program designed for maintenance of certification. *Pediatrics* 2014;**134**(1):e242-e248.
186. Blackwell DL. Modeling receipt of influenza A(H1N1)pdm09 vaccinations among US children during the 2009-2010 flu season: Findings from the 2010 National Health Interview Survey. *Med Care* 2015;**53**(2):191-198.



187. Aigbogun N, Hawker J, Stewart A. Interventions to increase influenza vaccination rates in children with high-risk conditions—A systematic review. *Vaccine* 2015;**33**(6):759-770.
188. Mazurek JM, White GE, Moorman JE, Storey E. Influenza Vaccination Among Persons with Work-Related Asthma. *Am J Prev Med* 2014;**47**(2):203-211.
189. O'Halloran AC, Lu P-j, Williams WW, Bridges CB, Singleton JA. Influenza Vaccination Coverage Among People With High-Risk Conditions in the US. *Am J Prev Med* 2016;**50**(e15-e26).
190. Lin CJ, Nowalk MP, Zimmerman RK, Moehling KK, Conti T, Allred NJ, et al. Reducing Racial Disparities in Influenza Vaccination Among Children With Asthma. *J Pediatr Health Care* 2016;**30**(3):208-215.
191. Shoup JA, Madrid C, Koehler C, Lamb C, Ellis J, Ritzwoller DP. Effectiveness and cost of influenza vaccine reminders for adults with asthma or chronic obstructive pulmonary disease. *Am J Manag Care* 2015;**21**(7):e405-413.
192. Skupin MK, Havstad S, Wegienka GR, Nageotte CG. Factors associated with rates of influenza vaccination in allergy and primary care clinics. *J Allergy Clin Immunol* 2015;**1**:AB237.
193. Hart RJ, Stevenson MD, Levine AJ, Bryant KA, Sikes KL, Paul RI. Assessing Intent and Willingness to Immunize Children Against Influenza in the Pediatric Emergency Department. Presented at the Southern Regional Meeting, New Orleans, 2014.
194. Lo H-y. Improving Influenza Vaccination Rates for Asthma Patients Admitted to Pediatric Hospital Medicine. In: 2014 AAP National Conference and Exhibition: American Academy of Pediatrics.
195. Regan A. The use of electronic health record data extraction for estimating influenza vaccination coverage and effectiveness. In: The 20th IEA World Congress of Epidemiology (17-21 August 2014, Anchorage, AK); 2014: WCE; 2014.
196. Jaiwong C, Ngamphaiboon J. Effects of inactivated influenza vaccine on respiratory illnesses and asthma-related events in children with mild persistent asthma in Asia. *Asian Pac J Allergy Immunol* 2015;**33**(1):3.
197. Yokouchi Y, Katsumori H, Shirakawa S, Fujiwara M, Kashima K, Kozawa R, et al. Protective effects of influenza A (H1N1) pandemic 2009 vaccination against the onset of influenza-like illness and asthma exacerbation in Japanese children. *Journal of Asthma: Official Journal of the Association for the Care of Asthma* 2014;**51**(8):825-831.
198. Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014. *Vaccine* 2015;**33**(16):1987-1992.
199. Biggerstaff M, Jhung M, Reed C, Garg S, Balluz L, Fry A, et al. Impact of medical and behavioural factors on influenza-like illness, healthcare-seeking, and antiviral treatment during the 2009 H1N1 pandemic: USA, 2009–2010. *Epidemiol Infect* 2014;**142**(01):114-125.

## Acknowledgements

We thank Dr Ron Hogg (OmniScience SA, Geneva, Switzerland) for his excellent medical writing services and ADME Osterhaus (affiliation) for his endorsement of this review as the chair of the European Scientific Working group on Influenza (ESWI). The work was supported by the European Academy of Allergy and Clinical Immunology (EAACI).

**Author contributions**

All authors are members of the EAACI Influenza and Asthma Task Force. Skevaki and Schwarze conceived and designed the study. Aziz Sheikh developed the search protocol. Ather Akhlaq, Ulugbek Nurmatov performed the systematic literature search, reviewed and selected the relevant publications. All authors except the former three performed data extraction, compiled the summary tables, contributed to interpretation of results and contributed to writing the first draft of the manuscript, which was reviewed by Skevaki and Schwarze and then revised by all authors. All authors approved the final version of the manuscript.

**Author conflict of interest**

The authors declare no conflict of interest.

**Table 1. Studies included in the systematic review, by section**

**Section 2a. Influenza-attributable health care utilization in asthma patients**

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
Chacon et al. 2015 (174)	Guatemala	May 2009 - June 2010	Epidemiological retrospective study	NA	Demographic and clinical characteristics of deaths associated with influenza A (H1N1) pdm09.	History of Asthma in 11% of the 112 dead patients with a pre-existing medical condition (7% children < 5 years, 11% people aged 5-59, 16% people aged 60+ and 18% of the 14 dead pregnant or postpartum women)	183 children and adults aged 0-60+ years. SARI decedents who tested positive for influenza.	Study performed in seven Central America Countries.
Dawood et al. 2014 (49)	USA	2003-2009 (seasonal) 2009-2010 (H1N1)	Epidemiological retrospective, population-based study	NA	Frequency and severity of influenza complications in hospitalized children.	History of asthma in 31% of children hospitalized for seasonal influenza vs. 42% in children hospitalized for influenza A (H1N1).  Asthma exacerbation as a complication in 27% of children with influenza A vs. 18% in children with seasonal influenza (overall, 22% of total).	6769 children and adolescents aged <18 years hospitalized for both seasonal and H1N1 influenza.	
Hagerman et al. 2015 (175)	Switzerland	June 2009 - Jan 2010	Prospective/ retrospective study performed in 11 hospitals	NA	Clinical characteristics of the influenza-hospitalized children.	Asthma 12% among the comorbidities of the 126 influenza-hospitalized children.	326 patients aged ≤18 years (189 <5 years; 126 with comorbidities hospitalized in eleven children's hospitals in Switzerland with a positive influenza A/H1N1/09 RT-PCR from a	Study performed in 11 hospitals in Switzerland.

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
							nasopharyngeal specimen.	
Jiang et al. 2015 (71)	China	Dec 2008 - June 2014	Epidemiological retrospective study	NA	Clinical characteristics and severe case risk factors for adult inpatient cases of confirmed influenza.	Out of the 240 (7.8%) cases of laboratory-confirmed influenza, (H1N, pdm2009 and H3N2), asthma was the most important risk factor for severe cases (RR = 15.200, 95% CI: 1.157-199.633).	240 adults aged ≥15 years consistent with SARI case definition who were monitored by SARI sentinel hospitals in ten cities in China.	Data extrapolated from abstract in English. Study performed in ten provinces of China.
Kwon et al. 2014 (176)	South Korea	May 2010 - Apr 2011	Retrospective study	NA	Prevalence of year-round respiratory viral infection in children with LRTI and the relationship between respiratory viral infection and allergen sensitization in exacerbating asthma.	Influenza virus was detected in 7 (25%) of the 28 asthma patients hospitalized for asthma exacerbation.  18 asthmatics (64.3%) had atopic sensitization.  Influenza virus responsible for asthma exacerbations with an OR 11.9 (1.5-90.4) for atopic asthma, 0.9 (0.1-12.3) for non-atopic asthma, 4.0 (1.2-13.8) for asthma in general.	309 children (median age 26 months) who were hospitalized for acute LRTIs (pneumonia, bronchitis, bronchiolitis or asthma).	
Park et al. 2013 (177)	South Korea	Jan - Dec 2009	Multi-site case-control study	NA	Association of asthma status and severity of H1N1 influenza in adults.	Of the 91 cases, 12(13%) and 3 of 54 controls (5%) were asthmatics (p=NS); of those without other comorbidities except asthma, 8 of 56 cases (14%) and 2 of 49 (4%)	91 cases (47.3±21.1 years) with a positive PCR for H1N1 influenza and were admitted to the ICU or general ward with a	

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
						controls had asthma (p=NS).	diagnosis of H1N1 influenza.  56 controls (45.0±20.6 years) with a positive PCR for H1N1 influenza, but were not admitted to hospitals.	
Placzek et al. 2014 (178)	USA	Oct 2008 - Apr 2009 (seasonal influenza)  Apr 2009 - Sept 2009 (H1N1)	Epidemiological retrospective study	NA	Association of age and comorbidity on 2008-2009 seasonal influenza and 2009 Influenza A (H1N1)-related ICU stay.	Asthma was the most prevalent risk factor for hospitalization, occurring in 28% (n=148) of the pH1N1 population, and 24% (n=174) of those with seasonal influenza.	1254 children and adults aged <5-64 years with seasonal and H1N1 influenza admitted to an ICU.	
Stripeli et al. 2015 (179)	Greece	Oct 2009 - Feb 2010 and  Jan 2011 - May 2011 (pH1N1)  2002 -2003 and 2004 - 2005 (Influenza A)	Epidemiological retrospective study	NA	Epidemiological and clinical characteristics of children hospitalized with pH1N1 compared with those of children hospitalized with seasonal influenza A in previous years.	Asthma was the most common underlying illness in both cohorts, but it was considerably more prevalent in the seasonal influenza group (19% vs. 7%; P=0.048).	146 children with pH1N1 aged 0-14 years and 138 children with seasonal influenza aged 6 months-14 years who were hospitalized for both pH1N1 and influenza A.	
Taha 2014 (57)	Saudi Arabia	June 2009 - Feb 2010	Retrospective cohort study	NA	Characteristics of pregnant Women admitted with 2009 H1N1 Influenza in a referral maternity hospital.	Bronchial asthma was present in 15 (45.5%) of pregnant women admitted with influenza.	33 pregnant women; mean age 27.7±5.6 years.	

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
Tam et al. 2014 (180)	USA	2007-2011	Retrospective population-based study (chart reviews)	NA	Influenza-related hospitalization of adults associated with low census tract, socioeconomic status and female sex.	Asthma was increasingly prevalent among cases with progressively higher census tract poverty status (16.4% in low poverty vs. 37.7% in high poverty).  Females overall and in each age group were more likely to have asthma (overall, 27.6% vs. 16.7%; $P<0.001$ ).	1094 hospitalized adults aged 18-65+ years with laboratory-confirmed influenza.	

ICU intensive care unit; NS not significant; LRTI lower respiratory tract infection; RR risk ratio; CI confidence interval; OR odds ratio; RT-PCR reverse transcriptase polymerase chain reaction; SARI severe acute respiratory infection.

## Section 2b. Influenza-induced acute asthma exacerbations

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding (absolute number of positive samples)	Population characteristics	Limitations/ comments*
<b>CHILDREN</b>								
Azevedo et al. 2003 (75)	Brazil	ND	Retrospective	NA	Laboratory confirmed IFV/ culture and IFA	0.0% (0)	36 children aged 2-14 years	
Thumerelle et al. 2003 (83)	France	1 Oct 1998 - 30 June 1999	Prospective	NA	Laboratory confirmed IFV/IFA, serology or both	3.6% (3)	82 inpatients aged 2-16 years	
Biscardi et al. 2004 (86)	France	1 Jan 1999 - 30 June 2001	Prospective	NA	Laboratory confirmed IFV/culture and IFA	3.4% (4)	119 inpatients aged 2-15 years	
						0.0% (0)	51 first episode (initial asthma)	
Bueving et al. 2004 (81)	Netherlands	1999-2001	Double-blind, randomized, placebo-controlled trial	Inactivated influenza vaccine vs placebo	Laboratory confirmed IFV/ culture, IFA and RT-PCR	7.2% (17)	235 children aged 6-18 years	Low number of IFV positive samples in first season-compensated by recruitment of higher number of subjects in second season
Johnston et al. 2005 (79)	Canada	10-30 Sept 2001	Prospective	NA	Laboratory confirmed IFV/PCR	0.0% (0)	52 children aged 5-15 years	
Ketsuriani et al. 2007 (80)	USA	Mar 2003 - Feb 2004	Prospective	NA	Laboratory confirmed IFV/PCR	0.0% (0)	65 children aged 2-17 years	Modest sample size
	USA	2002-2004	Prospective	NA		15.5% (38)	245 outpatients	



Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding (absolute number of positive samples)	Population characteristics	Limitations/ comments*
Miller et al. 2008 (63)					Laboratory confirmed IFV/PCR or culture	3.7% (19)	513 inpatients aged 6-59 months	
Vallet et al. 2009 (84)	France	1 Oct 2005 - 30 Nov 2007	Prospective	NA	Laboratory confirmed IFV/IFA	2.4% (4)	166 inpatients aged 2-15 years	
Kwon et al. 2013 (176)	Korea	Apr 2010 - Apr 2011	Prospective	NA	Laboratory confirmed IFV/RT-PCR	25.0% (7)	28 inpatients aged 60±34 months (Mean±SD)	Modest sample size, selection of the study population, short duration (1 year) of the study, single medical center, and subjects were limited to children with LRTIs severe enough to require hospitalization.
Mandelcwaig et al. 2010 (82)	France	Nov 2005 - Mar 2009	Retrospective	NA	Laboratory confirmed IFV/ IFA	14.0% (15)	107 outpatients	
						2.6% (6)	232 inpatients aged 1.5-15 years	
ADULTS								
Wark et al. 2001 (72)	Australia/UK	2 Feb - 1 Dec 1998	Prospective	NA	Laboratory confirmed IFV/RT-PCR, serology, culture and IFA	24% (12)	49 outpatients aged 16-74 years	

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding (absolute number of positive samples)	Population characteristics	Limitations/ comments*
Simpson et al. 2003 (74)	Australia/UK	ND	Prospective	NA	Laboratory confirmed IFV/PCR or serology or IFA	PCR screening: 24.0% (12) Serology screening: 18.4% (9) IFA screening: 2.0% (1)	49 inpatients aged 16-74 years	
Tan et al. 2003 (78)	Singapore	ND	Prospective	NA	Laboratory confirmed IFV/RT-PCR, dot blot and DIG-probe hybridization	20.7% (6)	29 inpatients aged 42±15 years (Mean±SD)	Uneven sex distribution (prevalence of females in acute asthma group).
Iikura et al. 2014 (76)	Japan	May 2011-Dec 2012	Prospective	NA	Laboratory confirmed IFV/RT-PCR	10.0% (5)	50 inpatients aged 28-92 years	Although 98% of patients had a common cold history receding their AAE, a pathogen was detected from nasopharyngeal swabs in only 70% of cases. Overall, 15 major viruses and 6 major bacteria were evaluated by multiplex PCR analysis. It is possible that other minor pathogens may be involved in AAE. Other potential

Authors, Year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding (absolute number of positive samples)	Population characteristics	Limitations/ comments*
								reasons for the low yield include inappropriate timing of sampling, lower respiratory tract infections, misinterpretation of allergic rhinitis symptoms, and single testing upon admission.
Teichtal et al. 1997 (77)	Australia	Aug 1993-July 1994	Prospective	NA	Laboratory confirmed IFV/Culture and serology	19.0% (15)	79 inpatients aged 16-66 years	
Atmar et al. 1998 (73)	USA	6 Dec 1991-3 May 1994	Prospective	NA	Laboratory confirmed IFV/Culture, serology and RT-PCR	37.9% (11)	29 inpatients aged 19-50 years	
		9 Dec 1992-31 May 1993	Cross-sectional			9.8% (12)	122 outpatients aged 17-77 years	

\*as reported in the original article

### 3a. Current influenza vaccine recommendations for people with asthma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population characteristics	Limitations/comments
Grohskopf et al. 2014 (181)	USA	2013-2014	National Recommendations after reviewing literature based on GRADE approach	LAIV and IIV in asthma	Efficacy and safety	Advise that children between 2-4 years who have asthma or wheezing in previous 12 months should not be given LAIV.	Adults and children including those with asthma. Population size unavailable.	
Grohskopf et al. 2015 (153)	USA	2014 - 2015	National Recommendations after reviewing literature based on GRADE approach	LAIV and IIV in asthma	Efficacy and safety	-	All adults and children including those with asthma. Population size unavailable.	No change from 2014 - 2015
Byington et al. 2014 (182)	USA	2013 - 2014	National Recommendations from American Academy of Paediatrics	LAIV and IIV in asthma	Efficacy and safety	Annual vaccination (trivalent or quadrivalent) recommended for everyone with special effort made towards asthmatics.  Asthma present in 26% hospitalized children with confirmed influenza during the 2013-14 season.	All children aged >6 months including those with asthma. Population size unavailable.	

LAIV live attenuated influenza vaccine; IIV inactivated influenza vaccine

### Section 3b. Current influenza vaccine coverage for people with asthma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population Characteristics	Limitations/ comments
Koshio et al. 2014 (132)	Japan	Sept-Oct 2010	Questionnaire-based cross-sectional survey	NA	Receipt of H1N1 vaccine and infection status as well as recording of ACT score.	Incidence of H1N1 pdm09 infection 6.7% (95% CI 5.7–7.6).  Vaccine receipt in 63.9% (95% CI 62.1–65.8%).  Infected patients (n=170) had significantly lower rates of vaccination, were younger and had experienced more night symptoms and sleep disturbance in the preceding 2 weeks.	2,555 asthma patients, aged ≥16 years.	Good characterization of asthmatics but no objective definition of influenza infection.
Pennant et al. 2015 (183)	USA	2009-2015	Prospective interventional quality improvement study	Physician reminders, patient letters, nurse-driven	Change in vaccination uptake rate.	Vaccine receipt improved from 59% to 64% between 2011 and 2014 influenza seasons.	1142 asthma patients in an allergy clinic aged ≥13 years (85 declined vaccine).	
Gnatiuc et al. 2015 (184)	Global (23 countries)	2008 onward	International cross sectional survey comparing high income and low-middle income countries	Participants with doctor diagnosed asthma underwent reversibility testing with salbutamol	Use of respiratory medicines and uptake of influenza vaccine in preceding 12 months.	Overall influenza vaccination uptake rates: 1.4% in LMIC vs. 28.4% in HIC ( $P = 0.0001$ ).	15,590 adults with asthma and COPD, aged ≥40 years (unclear what proportion are asthmatic).	Rare example of research comparing multiple countries from across the income spectrum  The age criteria for the study likely excluded a large

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population Characteristics	Limitations/ comments
								proportion of asthmatics
Vernacchio et al. 2014 (185)	USA	2009-2012	Learning collaborative model	Regular face to face meetings and electronic communication between healthcare teams	Uptake of influenza seasonal vaccination. Uptake of asthma action plans.	Inconsistent improvements in rates of vaccine uptake. Significant increase in implementation of asthma action plans.	594 patients with persistent asthma, aged 5-17 years.	
Blackwell et al. 2015 (186)	USA	2009-2010	Cross-sectional survey	Telephone survey	Receipt of vaccine in previous 12 months.	Asthmatics receiving H1N1 vaccine: OR 1.13 (CI 0.97-1.33).	667 children, aged 4 months to 17 years, including asthmatics.	
Aigbogun et al. 2015 (187)	Global	2014	Systematic review	NA	Uptake of vaccination rates in high-risk children.	Reminder letters useful in improving uptake but less evidence for telephone recall.	9 studies in children with asthma, aged 6 months to 19 years.	
Mazurek et al. 2014 (188)	USA	2006-2009	Cross-sectional survey	Telephone survey	Influenza vaccination uptake in the preceding 12 months.	42.7% uptake rate. Higher rates in those aged 50-64 years, unemployment and in those requiring urgent treatment for worsening symptoms.	28,809 adults aged 18-64 years with work-related asthma.	
O'Halloran, 2015 (189)	USA	2012-2013	Cross-sectional survey	Telephone survey	Influenza vaccination uptake in the preceding 12 months.	Uptake rate of 29% (95% CI 26.5-31.7%).	8,831 adults, aged 18-64 years with "pulmonary disease".	
Lin et al. 2015 (190)	USA	2010-2013	Prospective interventional quality	Utilized the "4 pillars	Influenza vaccination rates pre and post intervention.	Uptake rates increased between 2010-11 to 2012-2013 seasons in: Non-White	8,250 asthmatic children aged 6 months-18 years.	This intervention reduced the racial

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population Characteristics	Limitations/ comments
			improvement study	immunization toolkit"		children: 46% to 61%; White children: 58% to 65%.		disparity seen in vaccination uptake rates.
Shoup et al. 2015 (191)	USA	2012-2013	Pragmatic 3-arm randomized control trial	Three arms: 1. Postcard reminder 2. Telephone reminder 3. Postcard & telephone reminder	Change in influenza vaccination rate.	No difference in intervention groups.  Telephone (interactive voice response) calls were most cost-effective.	12,285 adults aged 19-64 years with asthma or COPD.	
Buyuktiryaki <i>et al.</i> 2014 (109)	Turkey	2010	Cross-sectional survey of parents	Questionnaire	H1N1 and seasonal influenza vaccination rates with analysis of demographic factors, asthma control parameters and parental attitudes towards vaccination.	16.8 % received H1N1 vaccine; 45.7% received seasonal vaccine.  Significant factors influencing uptake included low educational background of parents, previous vaccination with seasonal influenza and having a family member vaccinated against Influenza A/H1N1.  Asthma control parameters had no influence on uptake of the vaccine and physician recommendation (84.8%) was important in the decision-making process for immunization.	625 children and adolescents aged 6-18 years with asthma.	
Skupin et al. 2015 (192)	USA	2013	Cross-sectional survey	Questionnaire	Influenza vaccination uptake in preceding year.	Black patients had much lower vaccination rates	472 adults attending internal	



Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population Characteristics	Limitations/ comments
						(62.1%) than White (83.8%) or Asian (93.3%) patients.  Belief in efficacy in vaccine and physicians recommendation important determinants in higher vaccination rates.	medicine and allergy clinics.	
Hart et al. 2014 (193)	USA	2013	Cross-sectional survey	Structured interview	Vaccination uptake in previous year and parental intent to vaccinate in upcoming flu season.	64% (95% CI 59-70%) received vaccine in previous year.  37% of those parents with intent to vaccinate did not actually do so.	224 children, aged 6 months-17 years, attending paediatric emergency department.	Unclear what proportion are asthmatic at baseline.
Lo, 2014 (194)	USA	2013-2014	Prospective interventional quality improvement study	Implementation of influenza immunization bundle	Vaccination rate pre- and post-intervention.	Vaccination rate improvement from 19% (6-26%) to 39% (9-55%).	117 children attending hospital with asthma exacerbation.	
Regan, 2014 (195)	Australia	2013	Cross-sectional survey of electronic outpatient records	NA	Assessment of proportion of people immunized and estimate of vaccine effectiveness.	29.7% vaccination rate in asthmatics vs. 52.2% in those with coronary heart disease.  In all patients, combined clinical and pathological data suggested vaccination had effectiveness of 56% in preventing infection: OR 0.44 (95% CI 0.24-0.79).	2731 general practice patients with clinical and pathological data.	

ACT asthma control test; LMIC low-middle income countries; HIC high-income countries; COPD chronic obstructive pulmonary disease OR odds ratio; CI confidence interval; NA not available;



#### Section 4. Immunogenicity of influenza vaccines in asthma

Authors, year	Country	Study period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/comments
Bae et al. 2013 (121)	Korea	2011-2012 influenza season	Phase 4, multi-center, open label study	TIV (H1N1, H3N2, B) (7.5 µg per strain) Two doses in vaccine naïve children; one dose in previously vaccinated Interval between first and second dose not stated.	Short-term seroconversion rates, seroprotection rates, GMT, and GMT ratio; HI assay Safety: local and systemic adverse events.	Seroconversion and seroprotection rates in wheezers were similar to healthy children and significant for all 3 strains. The GMT was higher in the one dose-group vs. the two-dose group both in healthy children and in wheezers. The GMT ratio was significantly higher in healthy children than wheezers for the H1N1, H3N2 strains. No difference between steroid-treated and non-treated wheezers.	68 healthy children and 62 recurrent wheezers aged 6 months to 3 years.	Chronic and high dose ICS excluded. No adjustment for ICS dose.  Age significantly lower in healthy controls (1-2 y) than in wheezers (2-3 y).
Busse et al. 2011 (124)	US	2009 influenza autumn season	Randomized, open-label study	Monovalent H1N1 tested at two doses (15 vs. 30 µg) twice at 21 days interval	Short term rates and GMT of seroconversion and seroprotection; HI assay and microneutralization.	The 2 dosing groups did not differ in seroconversion rates.  In mild-to-moderate asthma the two doses offered equal seroprotection.  In severe asthma seroprotection was significantly higher with the 30 µg dose  In severe asthmatics >60 years old the seroprotection was achieved only with the 30 µg dose The second dose provided no additional benefit.	Adolescents and adults (12-79) with asthma; special subgroup > 60 years with mild-to-moderate and severe asthma (including use of OCS).	No healthy controls for comparison.

Authors, year	Country	Study period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/comments
						Atopy, BMI, systemic corticosteroid or ICS dose had no influence on HI GMTs or on seroprotection rates.		
Pedrosa et al. 2009 (122)	Mexico	2001-2002 influenza season	Double-blind, placebo controlled, randomized study	Inactivated TIV (H1N1, H3N2,B); dose 15 µg per strain; twice at 28 days interval	Safety: local and systemic adverse events; lung function; short-term rate of seroconversion; HI assay.	Significant rate of seroconversion after the first and second dose for all 3 strains.	Children 5-9 years with mild intermittent and moderate asthma.	No healthy controls for comparison. Study funded by industry. Asthma severity assessed only as LF; no data on exacerbations. Subjects with a history of allergy to egg protein excluded. Previous influenza vaccination status not reported.
Zuccotti, et al. 2007 (123)	Italy	2005-2006 influenza season	Observational prospective open label multi-centre study	Virosomal-adjuvanted TIV (H1N1, H3N2,B); dose 15 µg per strain; single dose	Short (at one month) and long-term (at 6 months) seroconversion ( $\geq 1:40$ ) and seroprotection ( $\geq 1:10$ ); HI assay; both rate and fold-increase in GMT. Seroconversion and seroprotection in relation to pre-existing antibodies.	Seroconversion: Both rates and GMT significantly high at both 1 and 6 months for all 3 strains Better GMT increase for the B strain in children 6-9 years compared to 3-5 years. Seroprotection: At one month satisfactory in both age groups, decreased	Children with asthma aged 3-9 years (subgroups 3-5 years and 6-9 years).	No data on asthma severity. No healthy controls. More than 50% of children had pre-existing antibodies at baseline.

Authors, year	Country	Study period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/comments
					Safety: local and systemic adverse events.	seroprotection for H3N2 for children aged 6-9 years. At 6 months: >80% in children aged 6-9 years; significantly lower (<70%) in children aged 3-5 years. Both seroconversion and seroprotection to any specific strain significantly lower without pre-existing antibodies.		Baseline GMTs were relatively high for all 3 strains. Subjects with history of egg allergy and/or severe atopy were excluded.

BMI body mass index; ICS inhaled corticosteroids; LF lung function; GMT geometric mean titer; HI hemagglutinin inhibition; OCS oral corticosteroids; SPT skin prick test; TIV trivalent influenza vaccines

## Section 5. Efficacy of influenza vaccines in asthma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
Abadoglu et al. 2004 (125)	Turkey	Recruitment: Sept - Nov 2001. Follow-up until Mar 2002	Randomized, controlled trial	TIV vs. no vaccine	Frequency of URTI infections and asthma exacerbations during the winter following vaccination.	URTIs and asthma exacerbation rates similar between vaccinated and non-vaccinated groups = no protective effect.	Asthmatic adults aged 22-84 years. In total: 128 Vaccination: 86 Nothing: 42.	Lack of knowledge on rate of influenza epidemic in tested period or on the cause of URTI.  Relatively low number of subjects enrolled.
Bueving et al. 2004 (126)	The Netherlands	1999-2000 2000-2001	Double-blind, placebo controlled, randomized study	TIV vs. placebo	Symptom scores (to detect infection); pharyngeal swab and spirometry; quality of life (QoL).	In influenza-positive weeks of illness: - no effect was found for respiratory symptoms recorded in the diaries - moderately beneficial effect on QoL throughout the seasons: No differences for respiratory symptoms and QoL.	Asthmatic children aged 6-18 yrs.  In total: 696 (296 in 1999 -2000 and 400 in 2000 - 2001) 347: influenza vaccine and 349 placebo.	Relatively few influenza-positive weeks of illness.
Bueving et al. 2004 (81)	The Netherlands	1999-2000 2000-2001	Double-blind, placebo controlled, randomized study	TIV vs. placebo	Symptom scores (to detect infection)  Pharyngeal swab.  Blood samples for influenza virus -specific antibodies (immunogenicity).	Influenza vaccination did not result in a significant reduction of the number, severity, or duration of asthma exacerbations caused by influenza.	696 asthmatic children aged 6-18 years.	
Fayyaz Jahani et al. 2012 (127)	Iran	ND	Randomized, placebo-controlled study	TIV	Asthma exacerbations.	Lower asthma exacerbation rates	140 asthmatic children aged 6 to 60 months.	Conference abstract, thus

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
						following TIV (13%) than after placebo (53%).		limited information.
Fleming et al. 2006 (128)	Multicenter (UK & Europe)	Oct 2002 - May 2003	Reactive-CT to examine relative efficacy of CAIV-T vs. TIV	CAIV-T vs. TIV	Surveillance for influenza-like symptoms. Nasal swab viral culture culture-confirmed influenza illness. Primary efficacy endpoint: incidence of culture-confirmed influenza illness caused by a community-acquired subtype antigenically similar to that in the vaccine.	CAIV-T had a significantly greater relative efficacy of 35% compared with TIV. There was no evidence of a significant increase in adverse pulmonary outcomes for CAIV-T compared with TIV.  CAIV-T was well tolerated in children and adolescents with asthma.	Asthmatic children aged 6 to 17 years.  CAIV-T (n=1114) TIV (n=1115).	No placebo group, therefore the absolute efficacy of each vaccine cannot be calculated.
Ambrose et al. 2012 (131)			Meta-analysis of two randomized, multinational trials	CAIV-T vs. TIV	Culture confirmed influenza illness during the influenza surveillance period. Rate of wheezing, hospitalization, adverse events.	Children receiving LAIV had fewer cases of culture-confirmed influenza illness than TIV recipients.	1940 children aged 2-5 years with asthma or prior wheezing.	Post hoc definition of study cohorts, but this is in part addressed by the sub-population analysis.  Identification of subjects asthma or history of wheezing relied on investigator judgment without validation.

TIV trivalent influenza vaccines; URTI upper respiratory tract infection; QoL quality of life; CAIV-T trivalent, cold-adapted influenza vaccine; LAIV live attenuated influenza vaccine





## Section 6. Effectiveness of influenza vaccination in asthma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
Christy et al. 2004 (137)	USA	1996-1997	Retrospective nested case control study	Influenza vaccine	Asthma-related hospitalization, clinic and emergency department visits.	Adjusted OR (95% CI) associated with vaccine for asthma related: Hospitalization 1.9 (0.9-3.9). Clinic visit 2.9 (2.0-4.1). Emergency department visits 2.0 (1.2-3.1).	Primary care cohort. 400 randomly selected children with asthma who had been vaccinated, and 400 who had not. Age range 1-19 years.	Two groups were not balanced in terms of ethnicity and likelihood of receiving vaccine in previous year, but this was taken into account in adjusted analysis.  Study suggests that vaccine associated with worse outcomes. Patients with more severe asthma or those more likely to present may be more likely to have been vaccinated although controlling for these did not alter the results.
Hak 2005 (136)	Netherlands	1999-2000	Nested case control study	Influenza vaccination	All cause mortality, hospitalization, general practice visits for	High-risk children <18 years, 43% (10%-64%) of visits were prevented by	All age groups with long term medical	No separate analysis for asthma.

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
					influenza, pneumonia and other acute respiratory problems.	<p>vaccination after adjustment.</p> <p>High-risk adults (18-64 years) 78% of deaths (39-92%), 87% of hospitalizations (39-97%), and 26% of GP visits (7-47%) were prevented.</p> <p>Elderly persons vaccine prevented 50% of deaths (95% CI, 23-68%) and 48% of hospitalization (7-71%) were prevented.</p>	conditions. >75,000 patients in primary care cohort.	Adjusted for previous medical utilisation and comorbidities.
Herrera et al. 2007 (138)	USA	2003-2004	Case-control study	Influenza vaccine	Laboratory confirmed influenza report.	<p>Influenza: vaccine "efficacy" was 60% (43 - 72%) and 48% (21 -66%) among those without and with high-risk medical conditions.</p> <p>Influenza-related hospitalization: vaccine "efficacy" was 90% (68 - 97%) and 36% (0 -63%) against for persons without and with high-risk conditions.</p>	330 cases, 1055 randomly recruited controls. Age range 50-64 years.	<p>No separate data for asthma. Apparent effectiveness may be inflated by potential tendency to not test vaccinated people and miss an influenza diagnosis on a vaccinated patient. Authors say "efficacy" but study set up as an effectiveness study.</p> <p>Vaccine strains did not closely match</p>

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
								circulating influenza strains.
Koshio et al. 2014 (132)	Japan	Sept-Oct 2010	Survey	Vaccination against " new type of influenza": H1N1 pdm09.	Report of a "new type of influenza": H1N1 pdm09.	For influenza, OR (95% CI) for previous vaccination was 0.62 (0.42-0.90) for younger patients $\leq 61$ years); among older patients OR was 1.38 (0.66-2.89)  For infection-induced asthma exacerbation, OR (95% CI) for previous vaccination was 1.67 (0.60-4.66) for younger patients and 1.71 (0.50-5.83) for older ones.	2555 adults with asthma.	There may have been other differences between vaccinated and non-vaccinated patients that explained the difference in risk of influenza. Influenza cases were not laboratory proven. This study looked at pandemic rather than ordinary influenza.
Kramarz et al. 2001 (133)	USA	1993-1996	Population based, retrospective cohort study	Influenza vaccine	Exacerbation of asthma.	Adjusted incidence rate ratios of asthma exacerbations after vaccination were 0.78 (0.55-1.10), 0.59 (0.43-0.81), and 0.65 (0.52-0.80) compared with the period before vaccination during the 3 influenza seasons.	Children aged 1-6 years with asthma in 4 large health maintenance organizations. (>70,000 patients).	As a database-based analysis, the asthma diagnostic labelling and recording of asthma exacerbations may not be completely accurate.

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
								Differences in patients receiving vaccination may have explained the difference in exacerbations.  Adjusted for asthma severity.
Ong et al. 2009 (135)	USA		Survey	Influenza vaccine	Exacerbation of asthma defined by oral corticosteroid, hospital visit or emergency department visit.	In the multivariate analyses, current influenza vaccination status was independently associated with significantly decreased OR of using oral steroids in the previous 12 months (0.29, 0.10-0.84). There was no association with hospitalization (1.39; 0.340-5.67) nor emergency department visits.	80 children with asthma in a paediatric clinic.	Retrospective approach may have introduced recall bias.  Factors influencing likelihood of vaccination may have influenced likelihood of exacerbation, confounding the results.  Triggers other than influenza may have been responsibly for the exacerbation.
Smits et al. 2002 (134)	Netherlands	1995-1997	Retrospective cohort study	Inactive influenza vaccination	Physician diagnosed acute respiratory illness.	Vaccine effectiveness was 27% (-7 to 51%) after adjustments.	Children with asthma aged 0-12 years in primary care. Over 300	Patients vaccinated may have been different to

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
						For those <6 years, it was 55% (20 to 75%) compared with -5% (-81 to 39%) in older ones.	patients in each season.	others and these factors may have impacted on likelihood of developing respiratory illness. Adjusted for previous healthy utilization
Jaiwong et al. 2015 (196)	Thailand	June 2012 - Aug 2013	Cross-sectional non-randomized study	TIV vs. no vaccine	Respiratory illnesses and asthma-related events.	The immunized group had significantly reduced: acute respiratory tract illnesses; asthma exacerbations; ER visits; bronchodilator usage and systemic steroid administrations; number of hospitalizations ( $p < 0.001$ ) and their duration ( $p < 0.034$ ).	93 mild persistent asthmatic children aged 1-14 years (48 patients: 2 doses of inactivated influenza).	Non-randomized study. Small sample size. Lack of info related to other confounding factors in asthmatic exacerbations such as compliance and controller usage, other virus and bacterial infections, pollution, emotional conditions of the patient.
Yokoushi et al. 2014 (197)	Japan	May 2009 - Feb 2010	Retrospective, cross-sectional, questionnaire-based survey	Inactivated, split-virus, non-adjuvanted	Vaccination rates. Vaccine effectiveness against physician-diagnosed influenza A infection, and	Comparison of positive influenza diagnosis rates between vaccinated and unvaccinated children with	460 children with ( $n=144$ ) and without asthma ( $n=316$ ).	Other environmental factors that may cause asthma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
				monovalent vs. no vaccine	consecutive. asthma exacerbations.	<p>and without asthma showed that:</p> <p>Unvaccinated children with asthma had an elevated odds ratio (13.235; 95% CI; 5.564-32.134).</p> <p>Treatment for asthma exacerbations was needed in a larger proportion of unvaccinated children.</p> <p>Vaccine effectiveness against physician diagnosed influenza was 87% (95% CI, 78-93%) overall, 92% (95% CI, 81-96%) in children with asthma and 81% (95% CI, 63-91%) in children without asthma, respectively.</p>		<p>exacerbation were not considered. No data on atopic comorbidities. Retrospective study.</p> <p>Physician diagnosed influenza infection with or without a positive rapid antigen test result for influenza A during the pandemic period.</p>

ER emergency room; OR odds ratio; GP general practitioner; TIV trivalent influenza vaccine; CI confidence interval

## Section 7. Safety of influenza vaccines in asthma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population characteristics	Limitations/ comments
Greenhawt et al, 2012 (146)	USA	Oct 2010 - Mar 2012	Phase 1: randomized, controlled trial. Phase 2: retrospective, observational trial	Phase 1: Group A: graded 2 dose TIV challenge Group B: sham (saline) 1 <sup>st</sup> dose followed by full TIV dose  Phase 2: participants who declined study and received TIV from their allergist or had already received TIV in primary care.	Safety of TIV in egg-allergic children with severe allergy.	No allergic reactions were recorded.	Egg-allergic children with severe allergy (mean age 12 years). All patients had previous confirmed severe allergic reactions to egg.	
Howe et al. 2011 (147)	USA	Phase 1: Oct 2004-Feb 2009 Phase 2: 2009-2010	Phase 1: Retrospective, observational study. Phase 2: Prospective observational study.	TIV	Safety of TIV in egg-allergic and non-allergic patients.	No severe allergic reactions have been recorded.	Children	
Miller et al. 2003 (143)	USA		Double-blind, placebo controlled trial.	Influenza vaccine	T-cell immune response to vaccine components in patients with asthma who experience bronchospasm.	Increased influenza (but not egg) antigen-induced mononuclear cell proliferation, unrelated to asthma exacerbations after vaccine. No differences in cytokine production in response to either influenza or egg antigen in	Adults, mean age 43 years.	

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population characteristics	Limitations/ comments
						association with asthma exacerbations.  Bronchospasm after immunization is not related to vaccination.		
Chung et al. 2010 (144)	USA	2002-2009	Retrospective, observational study	Influenza vaccine	Tolerability of the vaccine, defined as the lack of localized or systemic adverse reactions, in egg-allergic and non-allergic patients.	95% of egg-allergic patients who received the vaccine skin test tolerated the influenza vaccine without any serious adverse reactions.	Children, 6 months - 18 years.	
Gagnon et al. 2010 (145)	Canada	Oct-Dec 2009	Prospective, observational study	Adjuvanted monovalent 2009 pandemic influenza A/H1N1 influenza vaccine	Risk of anaphylaxis in children with egg allergy administered an adjuvanted monovalent 2009 pandemic influenza A/H1N1 influenza vaccine.	No patient had an anaphylactic reaction.	Children and adults.	
Greenhawt et al. 2010 (149)	USA	Oct 2009-Feb 2010	Controlled, prospective trial	H1N1 influenza vaccine	Safety of administering H1N1 to egg-allergic patients compared with non-egg-allergic, paediatric, control patients.	No significant allergic reactions were recorded.	Children and adults aged 6 months to 24 years.	
Esposito et al. 2008 (148)	Italy	Nov-Dec 2007	Prospective study	Virosomal adjuvanted influenza vaccine	To evaluate whether the virosomal adjuvanted influenza vaccine that has been shown to have the lowest egg protein content could be administered to children with even severe egg	Administration of the whole vaccine was safe and well tolerated by all of the children, with no differences between those with and without egg allergy, or between those with egg allergy of different severity.	Children >3 years.	



Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population characteristics	Limitations/ comments
					allergy without any risk of allergic reactions.			
Castro et al. 2001 (140)	USA	Sep-Nov 2000	Multicenter, randomized, double blind, placebo-controlled, crossover trial	TIV or placebo	Safety of TIV in adults and children with asthma.	The frequency of asthma exacerbations was similar in the two weeks after the TIV or placebo injection. The exacerbation rates were similar in subgroups defined according to age, severity of asthma, and other factors.	Children and adults aged 3-64 years.	
Baxter et al. 2012 (141)	USA	Oct 2003 - March 2008	Prospective observational post-marketing study	LAIV, TIV or placebo.	Safety of LAIV, compared to TIV and placebo in children.	Asthma/wheezing major adverse events were not statistically increased in LAIV recipients. No anaphylaxis events occurred.	Children aged 5-17 years.	
Ambrose et al. 2012 (131)		Study 1: 2004-2005 Study 2: 2002-2003	Post-hoc analysis of two randomized, multinational trials of LAIV and TIV in children aged 6 - 71 months	LAIV vs. TIV	Safety of LAIV in asthmatic children younger than 6 years.	Wheezing, lower respiratory illness, and hospitalization were not significantly increased in children receiving LAIV compared with TIV. Increased upper respiratory symptoms and irritability were observed in LAIV recipients.	Children aged 2-5 years.	
Gaglani et al. 2008 (142)	USA	1998-2002	Open-label field trial	Trivalent LAIV	Safety of the intranasal LAIV3 in children with intermittent wheezing/asthma.	No increased risk for medically-attended acute respiratory illnesses, including asthma exacerbation.	Children aged 1.5-18 years.	

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key findings	Population characteristics	Limitations/ comments
Haber et al. 2015 (198)	USA	LAIV4 reports: 2013-2014 LAIV3 reports: 2010-2013	Analysis of reports received at the "Vaccine Adverse Event Reporting System"	LAIV4 vs. LAIV3	Medical records were reviewed for non-manufacturer serious reports (i.e., death, hospitalization, prolonged hospitalization, life-threatening illness, permanent disability) and reports of selected conditions of interest.	No new or unexpected safety concerns with LAIV4. The safety profile of LAIV4 was similar to LAIV3. Just over 94% of LAIV4 reports were non-serious and the most common adverse events were mild, self-limited conditions (e.g., fever, headache and cough).	Children and adults aged 2-49 years. 12.7 million doses of LAIV4 were distributed.	General limitations of passive surveillance.
Turner et al. 2015 (151)	UK	Sept 2013 - Jan 2014	Prospective, multi-centre, open-label, phase IV intervention study	LAIV	Clinical symptoms after LAIV administration to estimate incidence of 1. Allergic reaction within 2 hours, 2. Delayed allergic symptoms within 72 hours, 3. Non-allergic adverse events; and change in nasal airway patency (acoustic rhinometry).	LAIV appeared to be safe in children with egg allergy and additional asthma or recurrent wheeze. No systemic allergic reactions reported. Eight children had mild, self-limiting, potentially IgE-mediated allergic symptoms.  26 (9.4%; 95% CI for population, 6.2% to 13.4%) children experienced lower respiratory tract symptoms within 72 hours, including 13 with parent-reported wheeze. None of these episodes required medical intervention beyond routine treatment.	282 children with egg allergy aged 2-17 years.	The egg protein content of LAIV batches may vary, thus data from this study may not be applicable to future LAIV stocks in which egg content may be higher.

TIV trivalent influenza vaccine; LAIV live attenuated influenza vaccine; CI confidence interval

## Section 8. Antiviral treatment against influenza in patients with atshma

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
Johnston et al. 2005 (168)			Randomized study	Oseltamivir (2 mg/kg) or placebo twice daily, as a syrup	Effects of oseltamivir among influenza-infected children with asthma.	Oseltamivir is safe and well tolerated among asthmatic children, may reduce symptom duration and helps improve lung function and reduce asthma exacerbations during influenza infection.	Asthmatic children aged 6-12 years. Analysis was performed for both the intent-to-treat infected (n=179) and per protocol (n=162) populations.	
Lin et al.2006 (162)	China	2002-2003	Randomized, open-label, controlled trial	Oseltamivir 75 mg twice daily for 5 days (oseltamivir group), or symptomatic treatment (control group) within 48 h after symptom onset	Duration and severity of illness in influenza-infected patients, incidence of complications, antibiotic use, hospitalization and total medical cost.	Oseltamivir is effective and well tolerated in high-risk patients with chronic respiratory or cardiac diseases. It can reduce the duration and severity of influenza symptoms and decrease the incidence of secondary complications and antibiotic use, without increasing the total medical cost.	118 Chinese patients (mean age 48.1 years) with chronic respiratory diseases (chronic bronchitis, obstructive emphysema, bronchial asthma or bronchiectasis) or chronic cardiac disease.	Only 8 patients with bronchial asthma.
Cass et al. 2000 (166)	UK	2000	Double-blind, randomized, placebo controlled, two way cross-over study, 7 day wash out period.	10 mg zanamivir as a dry powder (265 mg) or a placebo, twice daily on day 1 and then four times daily from day 2 to day 14.	Safety of Zanamivir in asthmatics.	Zanamivir inhaled as a dry powder does not significantly affect the pulmonary function and airway responsiveness of subjects with mild/moderate asthma and therefore its use in such patients/subjects is not precluded.	13 subjects, aged 19-49 years, with asthma.	


Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
Shun-Shin et al. 2009 (169)			Systematic review and meta-analysis of randomized controlled trials	NA	Effects of the neuraminidase inhibitors oseltamivir and zanamivir in treatment of children with seasonal influenza and prevention of transmission to children in households.	Oseltamivir did not reduce asthma exacerbations or improve peak flow in children with asthma.	Children aged $\leq 12$ years in the community (not admitted to hospital) with confirmed or clinically suspected influenza.	Based on only one trial.
Jefferson et al. 2014 (170)			Systematic review	NA	Potential benefit and harm of oseltamivir by reviewing all clinical study reports (or similar document when no clinical study report exists) of randomized placebo controlled trials and regulatory comments.	Ozeltamivir had no effect in children with asthma, but there was an effect in otherwise healthy children.	Children and adults who either were healthy before exposure to respiratory agents or had a chronic illness (such as asthma, diabetes, hypertension) but excluding people with immune suppression.	
Jefferson et al. 2014 (171)			Cochrane review	NA	Potential benefit and harm of neuraminidase inhibitors for influenza in all age groups by reviewing all clinical study reports of published and unpublished randomized, placebo-controlled trials and regulatory comments.	For the treatment of adults, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% CI 8.4-25.1, $p < 0.0001$ ). This represents a reduction in the time to first alleviation of symptoms from 7 to 6.3 days. There was no effect in asthmatic children, but in otherwise healthy children there was a reduction by	All age groups. 53 trials in Stage 1 and 46 in Stage 2 (formal analysis), including 20 oseltamivir (9623 participants) and 26 zanamivir trials (14,628 participants).	

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
						29 hours (95% CI 12-47 hours, p=0.001).		
Watanabe, 2013 (173)	Japan	2009	Double-blind, randomized controlled trial	Laninamivir group: single inhalation of 40 mg laninamivir and placebo oseltamivir capsules twice daily for 5 days.  Oseltamivir group: one capsule (75 mg) of oseltamivir orally twice daily for 5 days and laninamivir placebo powder once on day 1.	Efficacy and safety of laninamivir octanoate, an inhaled neuraminidase inhibitor for the treatment of influenza patients with chronic respiratory diseases.	Laninamivir octanoate showed similar efficacy and safety to oseltamivir in the treatment of influenza, including that caused by influenza A(H1N1)2009, in patients with chronic respiratory diseases.	203 patients aged ≥20 years. Most patients had underlying bronchial asthma.	
Kohno 2011 (172)	Japan	Jan-May 2009	Multicenter, uncontrolled, randomized, double-blind study	Peramivir intravenously administered at 300 or 600 mg/day for 1 to 5 days, as needed	Efficacy and safety of the novel anti-influenza virus drug peramivir in high-risk patients.	In the 600 mg group about 50% shorter duration of illness. In 33% of patients adverse drug reactions, described as “not particularly problematic clinically” with quick recovery in all cases.	37 influenza patients, ≥20 years, with risk factors, including asthma.	5 patients with asthma were also taking steroids.
Biggerstaff et al. 2014 (199)	USA	2009-2010	USA state-based, random-digit-dialled	none	Influenza antiviral treatment prescription in influenza like illness (ILI).	26% of respondents with ILI received clinical influenza diagnosis. Of these 36% received	216,431 adults ≥18 years, non-institutionalized	Data in this study are self-reported and subject to

Authors, year	Country	Study Period	Type of study	Intervention	Outcome measure	Key finding	Population characteristics	Limitations/ comments
			telephone survey			antiviral treatment. Being younger and employed but not high-risk conditions, including asthma, were associated with antiviral treatment.		recall and social desirability bias.  Diagnosis and treatment are not verified.
Biggerstaff et al. 2014 (165)	USA	2010-2011	USA state-based, random-digit-dialled telephone survey	none	Influenza antiviral treatment prescription in influenza like illness (ILI).	Among adults with a physician diagnosis of influenza, 34% received antiviral treatment. Having asthma was not associated with antiviral treatment.	75,088 adults (18->65 years) and 15,649 children (0-17 years) were interviewed.	Data in this study are self-reported and subject to recall and social desirability bias.  Diagnosis and treatment arte not verified.

COPD chronic obstructive pulmonary disease; NAI neuraminidase inhibitor; CI confidence interval.

**Figure 1**



**Figure 1. Global seasonal influenza vaccination policies for people with asthma.** Source data obtained from following references: Europe<sup>1,2</sup>; Americas<sup>3,4</sup>; Africa<sup>5,6</sup>; Asia<sup>2,7-9</sup>; Oceania<sup>7</sup>. The following countries have vaccination policies for chronic disease, which includes asthma in the majority of cases: Argentina, Bahamas, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, Egypt, El Salvador, Fiji, Grenada, Ivory Coast, Mauritius, Mexico, Morocco, Panama, Paraguay, Peru, Philippines, Saint Lucia, Thailand, Trinidad and Tobago, Uruguay and Venezuela. This graphic is licenced by a Creative Commons Attribution-ShareAlike 3.0 Unported License: <http://gunn.co.nz/map>.

1. O'Flanagan, D et al. Seasonal influenza vaccination in EU / EEA, influenza season 2011-12, VENICE II Consortium. 2013;1-67.

2. WHO. *Evaluation of seasonal influenza vaccination policies and coverage in the WHO European Region. Results from the 2008/2009 and 2009/2010 influenza seasons Based on a joint VENICE–ECDC–WHO survey.* 2010;1–29.
3. Ropero-alvarez, AM *Influenza Vaccine Use In the Americas Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i.* Pan American Health Organization. 2014. <http://www.paho.org/revelac-i/>.
4. Ropero-Alvarez, AM et al. *Expansion of seasonal influenza vaccination in the Americas.* BMC Public Health. 2009;9:361.
5. Duque, J et al. *Influenza vaccines and influenza antiviral drugs in Africa: are they available and do guidelines for their use exist?* BMC Public Health. 2014;14:41.
6. Green, RJ et al. *Influenza Guideline for South Africa – Update 2008.* S. Afr. Med. J. 2008;98:224–230.
7. Dwyer, D et al. *Seasonal influenza vaccine policies, recommendations and use in the World Health Organization’s Western Pacific Region.* West. Pacific Surveill. response J. WPSAR. 2013;4:51–9.
8. Gupta, V et al. *Influenza vaccination guidelines and vaccine sales in Southeast Asia: 2008-2011.* 2012;PLoS One 7:e52842.
9. Kang, J. *Effectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy.* Korean J. Pediatr. 2014;57:164–170.



## Appendix 1

### Search strategy: Medline format

1. Respiratory Hypersensitivity/ or Bronchial Hyperractivity or Asthma/ or Status Asthmaticus/
2. (asthma or asthma exacerbation or asthma attack or acute asthma or acute asthmatic attack or asthmatic children or wheez\*).mp.
3. (bronchial disorder or airway reactivity or airway hyperresponsiveness or bronchial hyperreactivity or bronchial hyperresponsiveness or lung function or ventilatory function or FEV or FEF or FVC or PEF).mp.
4. or/1-3
5. Influenza, Human/ or Influenza vaccines/ or Influenza A virus or Influenza B virus or Influenzavirus C/ or Influenza A Virus, H5N1 Subtype/ or Influenza A Virus, H1N1 Subtype/ or Influenza A Virus, H3N2 Subtype/
6. exp Epidemiologic Studies/ or exp Intervention Studies/ or exp Evaluation Studies/ or exp Comparative Studies/ or exp Follow-up Studies/ or exp Prospective Studies/ or exp Cohort Studies/ or exp Case-Control Studies/ or exp Cross-Sectional Studies/
7. (prospectiv\* or cohort or birth cohort or analytical stud\* or cohort stud\* or case-control stud\* or cross-sectional stud\*).mp.
8. Review literature as Topic/ or systematic review.mp.
9. Clinical trial/ or Controlled Clinical Trial/ or Randomized Controlled Trial/
10. exp Placebos/ or exp Random Allocation/ or exp Double-Blind Method/ or exp Single-Blind Method/
11. (trial or clinical trial or controlled clinical trial or random\* or randomi?ed controlled trial or double-blind design or single blind design).mp.
12. exp Survey/ or survey.mp.
13. or/6-12
14. 4 AND 5 AND 13
15. limit 14 to yr="2000-2014"
16. limit 15 to human

### Search Strategy: free-field format

(Asthma or acute asthmatic attack or status asthmaticus or wheez\* or respiratory hypersensitivity or bronchial hyperreactivity or bronchial hyperresponsiveness or airway hyperreactivity or airway hyperresponsiveness)

AND

(Influenza, human or influenza vaccin\* or influenza A virus or influenza B virus or influenzavirus C or influenza A virus subtype H1N1 or Influenza A virus subtype H3N2 or Influenza A virus subtype H5N1)

AND

(Analytical stud\* or epidemiologic\* or compar\* or evaluat\* or follow-up or observation\* or cohort stud\* or case-control stud\* or cross-sectional stud\* or systematic review or intervention\* or trial\* or RCT or double-blind or single-blind or control\* or random\* or prospective or retrospective)